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Abstract 
Feline herpesvirus 1 (FHV-1) is a linear double-stranded DNA virus that causes 
approximately 50% of the upper respiratory tract infections and produces the most severe 
respiratory disease in domestic cats.  Primary ocular infection, as occurs in humans with 
the related virus, herpes simplex virus type 1 (HSV-1), consistently produces 
conjunctivitis and minimal corneal involvement; however, clinical manifestations of 
disease due to repeated recrudescence involve the cornea and can potentially lead to 
blindness.  Vaccines only produce partial protection from clinical disease, and antiviral 
medications approved for treatment of HSV-1 in humans are only minimally effective for 
treatment of the chronic cases in cats.  Therefore, RNA interference (RNAi), a RNA-
guided gene regulatory mechanism that is found in a variety of eukaryotic organisms and 
provides anti-viral immunity in plants, was used as a therapeutic method for prevention 
of FHV-1 infection in feline cells.  Previous RNAi experiments in related herpesviruses 
demonstrated that the DNA polymerase gene and a gene coding for a viral attachment 
protein are effective targets for inhibiting herpesvirus replication.  Therefore, a region 
coding for highly conserved amino acid motifs of herpesvirus DNA polymerase genes, 
which is unique to each viral species and lacks DNA sequence drift for 
alphaherpesviruses, including herpes simplex virus type 2 and also feline herpesvirus as 
shown in this study, was targeted by RNAi.  The attachment proteins for FHV-1 are 
unknown, but the highly conserved glycoprotein D (gD) gene was also chosen as a target 
for this study.  HSV-1 gD is an essential receptor-binding polypeptide and is necessary 
for penetration of the virus into cells.  FHV-1 gD, an envelope protein, is an inducer of 
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virus-neutralizing antibodies and may play an important role in the restriction of the host 
range of the virus to feline cells.  
Two synthetic siRNAs targeting the DNA polymerase gene and the gD gene of 
FHV-1 were effective in knockdown of their intended targets by 69-83% for DNA 
polymerase mRNA and 77-87% for gD mRNA, determined by quantitative real-time RT-
PCR.  Based on flow cytometry results, glycoprotein D mRNA knockdown decreased gD 
cell surface expression by 27-43%, and DNA polymerase mRNA interference decreased 
cell surface FHV-1 glycoprotein expression by 29-71%.  Knockdown of the mRNAs 
from these genes also resulted in decreased infective virus in vitro, with decreased viral 
replication by 83-96% by DNA polymerase RNAi and 77-84% by gD RNAi, determined 
by plaque assays.  Interference of each mRNA also resulted in a decrease in the amount 
of the opposite mRNA, independent of interferon β production.  These results indicate 
that FHV-1 glycoprotein D, like its homolog in HSV-1, is essential for in vitro replication 
and is likely involved with viral attachment and/or penetration, and both this gene and the 
FHV-1 DNA polymerase gene are suitable targets for RNAi anti-viral treatment.  This 
study lays the groundwork for potential in vivo investigations in cats.  Such studies may 
provide unique insights into the prevention/treatment of herpesvirus infections by RNAi. 
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Part 1  General Introduction 
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Introduction 
Feline herpesvirus 1 (FHV-1) is a linear double-stranded DNA virus (185) that 
causes approximately 50% of the upper respiratory tract infections (140) and produces 
the most severe respiratory disease in domestic cats (173).  This virus is labile in nature 
but maintains itself by producing latent infections in its host (55).  Killed and modified 
live vaccines are available for FHV-1, but because the virus is poorly immunogenic (8), 
the vaccines do not prevent infection and only produce partial protection from clinical 
disease (21).  Acute infections are usually localized to the respiratory tract and clinical 
signs, though potentially severe, usually resolve in a few weeks (173).  However, chronic 
disease in latently infected cats is problematic.  First, diagnosing the disease is difficult in 
these cats (140).  Approximately 70% of cats are seropositive for the virus (106), and 
about 80% of infected cats become latently infected (55).  Though the majority of latently 
infected cats do not develop chronic clinical disease (6), there is still a large percentage of 
adult cats that have this problem (210).   Therefore, a positive test result may mean FHV-
1 is the cause of the disease, found coincidentally as a result of intermittent shedding, or 
present secondary to stress caused by a separate disease that is primarily responsible for 
the clinical signs (27, 137).  
Second, the clinical manifestations of disease due to repeated recrudescence, 
mainly affecting the eye, are significant and can potentially lead to blindness (6).  
Antiviral medications approved for treatment of a related virus, herpes simplex virus type 
1 in humans, are only minimally effective for treatment of these chronic cases in cats 
(212).  Therefore, development of a new therapeutic for FHV-1 would be beneficial.   
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Recently, RNA interference has been used for prevention of various mammalian 
viral infections both in vitro and in vivo (98).  RNA interference is a RNA-guided gene 
regulatory mechanism that is found in a variety of eukaryotic organisms, including yeast, 
plants, and mammals.  One of its biological functions is anti-viral immunity in plants 
(39).  This defense mechanism is triggered by double stranded RNA, and small 
interfering RNAs can be chemically produced and delivered to cells to silence specific 
genes of interest (47).  The purpose of this study was to determine the feasibility of using 
RNA interference to prevent feline herpesvirus 1 infections in vitro.  
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Feline Herpesvirus 1 Literature Review 
Feline herpesvirus 1 was first isolated in the United States in 1957 from a group 
of 5-10 week old kittens experiencing upper respiratory tract disease (38).  The virus was 
subsequently detected in many other countries, including Switzerland in 1963 (35), 
Hungary in 1965 (82), Canada in 1965 (46), Britain in 1966 (88), Australia in 1970 (216), 
and Japan in 1974 (125).  
Classification and viral properties:  FHV-1 is a member of the family 
Herpesviridae (46) and is classified in the subfamily Alphaherpesvirinae (184).  Based 
on phylogenetic analysis of its proteins, FHV-1 is grouped in the Varicellovirus genus 
(126, 246).   
FHV-1 has a diameter between 141 and 173 mµ, contains an icosahedral capsid 
comprising 162 capsomers, and has an envelope (34, 35).  The genome of FHV-1 is 
approximately 126-134 kbp, based on restriction endonuclease mapping (67, 185).  It has 
a G+C content of approximately 46% (172).  The genome consists of a single linear 
molecule of double-stranded DNA.  It is composed of a unique long region 
approximately 99-104kbp, which is covalently linked to a unique short sequence of 8-9 
kbp that is flanked by inverted repeats of 7-11 kpb each (67, 185).  The short region can 
invert its orientation relative to the long region, so the genome exists in two isomeric 
forms.  FHV-1 has a group D genome, which includes other alphaherpesviruses varicella-
zoster virus, pseudorabies virus, equine herpesvirus-1, and bovine herpesvirus-1.  The 
genome is most similar in size and arrangement to equine herpesvirus-1 (185). 
Viral transcription occurs in the host cell nucleus.  Three classes of mRNA, α 
(immediate early), β (early), and γ (late) are transcribed in sequence.  The immediate 
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early and early genes encode enzymes and DNA-binding proteins, and the late genes 
encode mainly structural proteins.  Viral DNA replication occurs in the nucleus and viral 
DNA is packaged into capsids within this compartment.  The virions acquire their 
envelopes by budding from the nuclear membrane (151).   
Host/tissue range and cytopathology:  FHV-1, unlike other alphaherpesviruses 
such as herpes simplex virus type 1 and pseudorabies virus, is restricted in vivo to Felidae 
and in vitro to feline cells (34, 35, 82, 111, 172, 175).  The virus replicates in cultures of 
feline origin including kidney, thymus, tongue, lung (175), cornea (188), tracheal organ 
cultures (113), and T-lymphocytes (78), and the virus has been isolated only in feline 
cells (35).   
FHV-1 grows rapidly in cell culture.  Infectious intracellular virus can be detected 
six hours post infection, and cell-to-cell spread of virus can be detected six to seven hours 
post infection.  Extracellular spread of the virus occurs at nine to ten hours post infection, 
concurrent with detection of infectious extracellular virus (236). 
The characteristic cytopathologic feature of FHV is the occurrence of type A 
intranuclear inclusion bodies, which are spherical or oval, acidophilic and separated from 
the nuclear membrane by a clear halo (34, 38).  FHV also develops multinucleated giant 
cells or syncytia in cell cultures, which consist of foci of cells that have lost their distinct 
cellular membranes and have fused with adjacent cells.  Infected cells are rounded or 
elongated in shape and are more retractile than uninfected cells (36). 
Antigenic and genomic properties:  There is antigenic homogeneity between 
isolates from many parts of the world compared to the prototype strain (177).  All isolates 
belong to one serotype, confirmed by virus neutralization, complement fixation, 
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immunodiffusion, and hemagglutination inhibition assays (175).  Minor differences 
between strains can be identified with immunoblot and restriction endonuclease analysis.  
Some isolates lack a 36 kDa protein, and the restriction enzyme MluI produces variable 
restriction patterns among strains, suggesting isolates can be divided into different groups 
based on genomic heterogeneity.  The importance of these differences in genomes with 
regard to virulence is unknown (80, 129).  The apparently low rate of variability between 
isolates suggests the genome has evolved to a fairly constant state, possibly through an 
interaction with the host cell DNA during latency or reflecting some inherent property of 
the virus (67). 
Viral genes and proteins:  FHV-1 contains at least twenty-three viral proteins 
(49).  Seven FHV-1 glycoproteins have been identified and each share sequence 
homology with other alphaherpesvirus glycoproteins.  Genes encoding glycoproteins B, 
C and H are located in the unique long segment of the genome (125).  FHV-1 
glycoprotein B homolog was identified in 1992 (126).  It is 2829 base pairs and contains 
two potential proteolytic cleavage sites (204).  In nonreducing conditions, glycoprotein B 
in virus infected cells has molecular masses of 143 kDa and 108 kDa, the latter likely 
represents the precursor form of the glycoprotein, which lacks glycosylation (79, 126).  
Under reduced conditions, glycoprotein B has molecular masses of 100 kDa, 64 kDa, and 
58 kDa.  Due to the potential cleavage sites in the sequence encoding this gene, the 
protein likely consists of a heterodimer or trimer (124).  Glycoprotein B is a major 
envelope glycoprotein of herpes simplex virus-1 and is crucial for virus infectivity.  This 
glycoprotein is involved with virus adsorption and penetration and cell-to-cell spread of 
the virus by fusion of susceptible cells (126).  Glycoprotein B is the most conserved 
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glycoprotein among herpesviruses, and some epitopes of FHV-1 cross-react with herpes 
simplex virus-1 antisera (79) and with monoclonals directed against canine herpesvirus 
glycoprotein B (118).   
The gene for glycoprotein C is 1602 base pairs in length and homologs are non-
essential for replication in vitro.  Glycoprotein C has molecular masses of 113 kDa and 
75 kDa (125).  The glycoprotein C of herpes simplex virus type 1 mediates the initial 
stage of virus attachment by binding heparan sulfate (133).  FHV-1 glycoprotein C has 
been demonstrated to bind heparin, indicating the role of FHV-1 glycoprotein C may be 
similar to herpes simplex virus glycoprotein C (132).  Some FHV-1 isolates have genetic 
rearrangements in the glycoprotein C gene, resulting in insertions of repeat sequences, 
but the relevance of the rearrangements is unknown (69). 
The gene encoding glycoprotein H is the second most highly conserved gene 
among herpesviruses.  In herpes simplex virus type 1 and pseudorabies virus, 
glycoprotein H is implicated in viral entry and direct cell-to-cell spread of virus and in 
membrane fusion.  This gene is located immediately downstream of the thymidine kinase 
gene and is predicted to encode 821 amino acids (127). 
Glycoproteins G, D, I, and E have been identified in the unique short segment of 
the genome.  FHV-1 glycoprotein D has a molecular weight of 53-59 kDa (77, 205).  The 
FHV-1 glycoprotein D gene appears highly conserved; nucleotide sequences from three 
different strains are identical (243).  Glycoprotein D has variable functions in different 
alphaherpesviruses.  Herpes simplex virus type1 glycoprotein D is necessary for virus 
growth.  Glycoprotein D negative mutants are unable to infect susceptible cells or spread 
by direct cell-to-cell transmission.  However, glycoprotein D in pseudorabies virus is not 
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essential for virus growth, and varicella-zoster virus lacks a glycoprotein D homolog 
(125).  The glycoprotein D homolog in FHV-1 has been identified as a hemagglutinin of 
feline red blood cells (63, 77, 128).  Hemagglutination titers are low (63), but the 
hemagglutination activity of FHV-1 is enhanced by treatment of the virus with 
polyoxyethylene sorbitan monooleate (Tween 80) and ether, resulting in separation of the 
glycoprotein from the envelope of the virus (147).   
FHV-1 glycoprotein D may play an important role in the restriction of the host 
range of the virus to feline cells (131).  FHV-1 does not hemagglutinate dog, chicken, or 
guinea pig red blood cells (63).  Insect cells expressing FHV-1 glycoprotein D bind only 
to feline cell lines, not porcine, bovine, or canine (131).  Monoclonal antibodies directed 
against glycoprotein D inhibit hemagglutination (79).  The hemagglutinins of FHV-1 and 
canine herpesvirus share common epitopes.  A monoclonal directed against the FHV-1 
hemagglutinin inhibits the hemagglutination activity of canine herpesvirus (118).   
Glycoprotein E and glycoprotein I form a hetero-oligomeric complex (146) and 
are involved in cell-to-cell transmission.  The complex is found on the surface of infected 
cells and these genes are non-essential for growth in cell culture (125).  However, an 
FHV-1 mutant containing a disrupted glycoprotein I gene produces a smaller plaque size 
than the parent virus (145).  Deletion of glycoprotein E and a portion of glycoprotein I 
results in reduced virulence when the mutant virus is administered oronasally, suggesting 
these are virulence genes (101). 
Glycoprotein G is expressed as a secreted protein or is bound to the membrane of 
infected cells.  It is also a structural protein, incorporated into the viral envelope.  
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Glycoprotein G functions as a chemokine binding protein, modulating the anti-viral 
chemokine defense system in the host (33). 
Glycoproteins B, C and D are also expressed on the surface of infected cells.  Cell 
membrane fluorescence can be demonstrated at 12 hours post-infection for glycoprotein 
C, 16 hours post-infection for glycoprotein D, and 20 hours post-infection for 
glycoprotein B.  Glycoprotein D has at least four distinct epitopes, glycoprotein C has 
two antigenic domains (one neutralizing domain consisting of three overlapping epitopes 
and a non-neutralizing domain), and glycoprotein B has only one antigenic site, 
consisting of five similar or overlapping epitopes (117).  Monoclonal antibodies produced 
against these glycoproteins exhibit virus neutralizing activity.  The neutralizing activity 
against glycoproteins B and C requires complement, but the neutralizing activity against 
glycoprotein D shows varying complement requirements.  This is possibly due to 
recognition of the different epitopes, but the majority of the anti-glycoprotein D 
monoclonals neutralize without need for complement (79).   
Latency:  Like other alphaherpesviruses, FHV-1 establishes latency in the 
trigeminal ganglion, as determined by explant /isolation techniques (53, 153) and 
polymerase chain reaction (PCR) (181, 218, 237).  More than 80% of cats become 
latently infected after acute FHV-1 infection, and at least 45% of those shed the virus 
(55).  The carrier state is characterized by periodic episodes of shedding.  Re-excretion of 
the virus can be stimulated by stress, such as changes in housing or parturition and 
lactation, or induced by injections of steroids (55, 57).  The mean lag time between the 
induction of stress and re-excretion of virus is seven days, with excretion lasting 1-13 
days.  Re-excretion may be associated with clinical signs such as mild conjunctivitis or 
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rhinitis or may not be associated with any clinical signs at all (55, 57). Spontaneous 
shedding also occurs without an association of clinical signs (55).   
Latency associated transcripts are detected in trigeminal ganglia of latently 
infected cats (163, 224).  These transcripts are the opposite strand of the immediate early 
gene of FHV-1 (163), and are considered to indicate a true state of latency when detected 
in tissue (211).  Other suggested latently infected tissues, determined by detecting non-
replicating virus by PCR, include the olfactory bulbs (56, 181, 218, 237), brain stem 
(218), optic nerves (237), and nasal turbinates (181).  The virus may also establish 
latency in the cornea (181, 224, 237), but latency associated transcripts have not been 
detected in the corneas of latently infected cats (224).  Isolation of infectious virus from 
tissues of latently infected cats is difficult, even from cats actively shedding virus.  This 
suggests either very little virus is present in the tissues, with few cells infected (163), or 
the virus is in a form that is non- infectious (56, 181).   
  Transmission:  FHV-1 has been perpetuated in nature as a result of its ability to 
produce latent infections, and latently infected cats represent the most important reservoir 
of the virus (55, 166).  Herpesvirus is unable to survive outside the host for more than 
three days.  Samples collected on swabs must be suspended in protein medium to allow 
survival up to 72 hours at room temperature.  Virus remains viable at room temperature 
no more than 18 hours on swabs suspended in saline (176).  Direct transmission between 
cats and persistence of the virus within cats is necessary for the perpetuation of the virus.  
Transmission occurs between shedding and susceptible cats only if there is intimate 
contact between them.  Widespread airborne transmission does not seem important in 
viral spread and FHV-1 is unlikely to be spread between cats by aerosol (58, 173).  The 
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virus can be spread by sneezed droplets and the probable effective distance for 
transmission is about three feet (177).  Spread by fomites is also a mode of transmission 
that is more likely to occur in cattery situations (175).   
Cats are territorial and do not naturally commingle.  This behavior reduces the 
contact between cats, decreasing the opportunity to spread respiratory infections.  
However, in situations in which cats are brought together from different sources and 
housed in close quarters, severe respiratory disease outbreaks may occur (92).  
Respiratory disease is most likely to occur in breeding colonies and rescue catteries and 
disease is most likely to be detected in younger cats, approximately 4-11 months old (16).  
Cats that have recently visited a boarding facility are also most likely to have respiratory 
disease (16), and cats in contact with cats outside the household are most likely to have 
detectable FHV-1 (219).  Poor hygiene within multi-cat households, including breeding 
facilities and rescue shelters, is also a risk for upper respiratory tract disease (75). 
Upper respiratory infections in cats is second only to overcrowding as the leading 
cause of euthanasia in shelters (9).  FHV-1 is one of the most important causes of shelter 
respiratory disease.  In one study, 41% of shelter cats had active FHV-1 infection (9), and 
in another study, shedding increased from 4% in cats upon relinquish to 52% after just 
one week within the shelter.  Though many cases are probably due to recrudescence, this 
also represents new cases, suggesting FHV-1 is spread rapidly and efficiently within 
shelters (170). 
 Prevalence:  FHV-1 is widespread within the feline population, with at least 
70.7% of cats serologically positive (106), but the seroprevalence may be as high as 97%, 
based on results from a more sensitive test (42, 140).  Prior to the development of 
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vaccines, the rate of infection in healthy cats, as determined by isolation from 
oropharyngeal swabs, was 1% from household cats and 1.75% from cat show cats.  
However, the true rate is likely higher because carriers shed intermittently (235).  Recent 
studies suggest the rate of carriers, determined by isolation of FHV-1 from conjunctival 
swabs (140) and detection of FHV-1 DNA by nested PCR from conjunctival snip 
biopsies (213) from clinically normal cats is 10.9% and 12%, respectively.  FHV-1 has 
been detected in 13.7%-54% of cats with naturally acquired conjunctivitis or respiratory 
disease (27, 140, 213).   
  Clinical disease:  The disease produced by FHV-1, designated feline viral 
rhinotracheitis (36), is the clinically most significant infection of the feline respiratory 
diseases (173).  The incubation period is usually 2-4 days (175), but the infecting dose is 
a significant factor in determining the length of the incubation period (54).  The acute 
disease is characterized by pyrexia, salivation, leukocytosis (primarily neutrophilia), 
depression, conjunctivitis, serous to mucopurulent ocular and nasal discharge, and 
accompanying coughing, sneezing and dyspnea (37, 38, 222).   Dendritic corneal ulcers 
may also develop but are less common during the acute infection (158), and are 
considered pathognomonic if present (160, 183).  The most significant lesions are 
produced in the upper respiratory tract, especially in the mucosa of nasal passages and 
turbinates, as a result of the cytopathic effects of the virus (37).  Osteolytic lesions can 
occur in nasal turbinate bone (76).  The virus has a limited ability to replicate at core 
body temperature, so the primary sites of replication are the cooler epithelial surfaces 
(211).  Thus, the main sites of viral replication are the nasal turbinates, conjunctivae, 
tonsils, soft palate, and trachea (37, 38, 56).  Experimental infection can be produced by 
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application of the virus to the mucosal membranes of the eyes, nose, or mouth, but 
disease does not occur with intramuscular injection of the virus (177).  Large amounts of 
virus are produced and released upon rupture of infected cells.  Shedding occurs in all 
discharges from the eyes, nose, and throat and infectious virus can be demonstrated in 
these secretions for a period of 1-3 weeks after primary infection (175, 177).   
Acute infection can occur in kittens, resulting in generalized disease and death 
(51, 206).  Less common manifestations of FHV-1 include skin ulcers (73, 90), interstitial 
pneumonia (120), and lingual ulcers (197).  Bronchial pneumonia can develop secondary 
to bacterial infection and conjunctivitis can lead to adhesion of the eyelids (82).  The 
clinical signs may be worse in immunosuppressed cats co-infected with feline leukemia 
virus or feline immunodeficiency virus (180, 217).  Mortality is high in young or 
debilitated cats, but the majority of cats recover in 7-10 days; however, the recovery may 
take weeks for severe cases (175). 
Abortions have also been associated with FHV-1 infection (76, 206).  Herpesvirus 
associated abortion in animals is due to viremia, rarely resulting from the spread of the 
disease from the lower genital tract.  Vaginitis can be experimentally produced by 
infecting the vaginal area.  Kittens born to queens infected in this manner in the later 
stages of gestation have high mortality rates due to generalized infection.  Some kittens in 
the study were born with respiratory disease, suggesting in utero infection (20).  
However, genital tract lesions have not been detected in natural infections (175).  Queens 
experimentally infected with FHV-1 intravenously or intranasally in the sixth week of 
gestation either abort or have dead fetuses.  Lesions are detected in the placenta, uterus, 
and in a fetus from queens inoculated intravenously, but not in those inoculated 
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intranasally (76).  In a study evaluating the transmission of the virus, no in utero 
infections were demonstrated (58).  Therefore, abortions occurring in natural infections 
are more likely due to severe maternal infection than to fetal infection with FHV-1.  
FHV-1 rarely causes viremia and has a low abortogenic potential, and abortions in 
naturally occurring infections are rare (201). 
FHV-1 is the only documented viral cause of feline keratits, and corneal 
ulceration is primarily seen in adult cats with recrudescence of latent virus.  Stromal 
keratits is a less common manifestation of FHV-1 infection and results from chronic 
recurrent episodes of FHV-1 keratitis.  Only a small percentage of cats will have 
recurrent bouts of keratitis, but this manifestation of FHV-1 infection is vision 
threatening, due to the associated stromal fibrosis and opacification.  The mechanism of 
stromal disease is unknown, but prolonged absence of corneal epithelium results in 
stromal keratitis (6).  This may be a function of the duration of the cornea’s exposure to 
virus, and after virus gains access to the stroma, keratitis may be mediated by an immune 
response to viral antigens with infiltration of infected tissues with neutrophils, followed 
by B and T lymphocytes (155).  Stromal keratitis does not occur in acute infection unless 
cats are treated intraocularly with steroids.  Intraocular steroid injections preceding FHV-
1 infection result in increased severity and prolonged infection with delayed 
epithelialization and suppressed collage synthesis, leading to stromal keratitis, 
characterized by geographic epithelial ulceration, interstitial edema and deep 
vascularization.  Other complications include decreased tear production and corneal 
sequestration, likely a nonspecific sequelae to significant stromal damage (155, 158).  
Recurring FHV-1 ocular disease may be unilateral or bilateral (212). 
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FHV-1 DNA has been detected in the corneas of a higher percentage of cats with 
eosinophilic keratitis or corneal sequestration than in corneas from clinically normal cats.  
Eosinophilic keratitis is a superficial proliferative inflammatory response of the cornea, 
predominated by mast cells and eosinophils.  Corneal sequestration results from 
degeneration of stromal collagen and accumulation of a dark brown or black pigment 
presumed to be of tear film origin (156).  FHV-1 has also been associated with uveitis.  
DNA has been detected in the aqueous humor from cats with uveitis.  It is believed FHV-
1 gains intraocular access via axonal transport along sensory nerve axons from the 
trigeminal ganglion, which innervates intraocular structures including the anterior uvea 
(139). 
FHV-1 may also play a role in chronic rhinosinusitis, but in one study, detection 
of FHV-1 DNA was not statistically different in cats with chronic rhinosinusitis versus 
control cats.  In the study, no actively replicating virus was detected in cats with chronic 
rhinosinusitis, so the disease does not appear the result of direct cell lysis (86).  However, 
increased nasal cytokine expression has been detected in cats with replicating FHV-1, 
suggesting FHV-1 does have some role in nasal inflammation (87). 
Immunoprophylaxis and immune response:  Many attenuated (intranasal (41, 
107) and parenteral) vaccines and an inactivated (parenteral) vaccine are available for 
FHV-1 in the United States (107).  The first documented successful vaccine was the F-2 
strain.  This was an attenuated vaccine, produced by multiple passages in cell culture, 
including some passages at low temperature, and was used intramuscularly.  The vaccine, 
like all FHV-1 vaccines developed since, produced significant reduction in the disease in 
vaccinated cats compared with unvaccinated cats, but it did not prevent disease in all the 
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cats tested (21, 22).  Vaccination also does not prevent chronic ocular manifestations of 
FHV-1 (212).  Vaccination does not prevent shedding of virus following challenge, and 
according to different studies, it may or may not decrease the course and amount of virus 
shedding (31, 107, 166, 195, 222, 238).  Vaccination does not prevent the establishment 
of a latent infection (165); although, vaccination with at least one strain showed a 
reduced latency load in the trigeminal ganglia of cats post challenge (218).  This may be 
beneficial, because attenuation of the amount of virus that reaches the sensory nerves 
results in a smaller reservoir of latent virus from which subsequent reactivations could 
arise (109). 
Intranasal vaccination may be superior to intramuscular vaccination, requiring one 
dose instead of two, and may provide better protection than parenteral vaccines because a 
local and or cell mediated immune response may be more important for protection than 
serum antibody (41, 166).  However, cats shed intranasal vaccine virus (166), and 
attenuated intranasal vaccine virus may establish latency (238).  Intranasal use of 
attenuated parenteral vaccine strains produces severe disease (41, 101, 218).   
The use of subunit vaccines may be useful in preventing establishment of a latent 
infection with a modified live recombinant vaccine (117).  Glycoproteins D and B are 
potential targets for subunit vaccines.  Glycoprotein D expressing vaccinia recombinants 
produced complement-independent virus neutralizing antibodies in immunized rabbits 
(205).  Also, FHV-1 glycoprotein D expressed in a recombinant baculovirus produced 
high virus neutralizing antibody titers in immunized mice (130).  Plasmid DNA 
expressing glycoprotein B injected into mice also produced virus neutralizing antibodies 
(123).  
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 FHV-1 stimulates a poor immune response.  Cats are susceptible to re-infection 
six months after primary infection.  FHV-1 may evade the immune system.  Because it is 
highly cell associated, matures intracellularly, and can spread cell to cell without contact 
with the interstitium, contact with neutralizing antibody is minimized (8).  The immune 
response develops with serum neutralizing antibodies appearing about day 16 post 
exposure, but antibodies may not be detectable in some cats until three weeks post 
exposure (35, 82, 175). 
 Vaccination does appear to produce long term partial protection from clinical 
disease.  Vaccination subcutaneously with an inactivated vaccine produced reduced 
severity of clinical disease following viral challenge 7.5 years after vaccination in cats.  
The vaccine provided persistent antibody titers for three years, and there was a rapid 
anamnestic response in the vaccinated cats post-challenge (195).  In another study, 
vaccination induced a serologic response that lasted at least 48 months (150), and in a 
separate study, vaccination provided protection from severe clinical disease 10 and 31 
months post vaccination (106).  Though detection of FHV-1 antibodies in vaccinated cats 
appears to correlate with protection from clinical disease, some cats lacking antibody 
titers may also be protected from disease.  This suggests the importance of cell mediated 
immunity or a rapid anamnestic response to FHV-1 infection (106). 
 A cell mediated immune response to FHV-1 develops in the cat and can be 
demonstrated in vitro.  The response is comprised of cytotoxic T cells and antibody 
dependent cell mediated cytotoxicity (221, 236).  FHV-1 infected cells can also be 
destroyed by antibody and complement mediated lysis (236).  Protection to FHV-1 
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appears to be due to a specific immune response, and local responses are likely to be 
involved (31). 
Passive immunity in kittens is acquired through colostrum and provides protection 
for 5-8 weeks but cannot be correlated with the antibody levels of the queen (58, 177).  
Shedding associated with the later stages of lactation, during the time of waning passive 
immunity, can result in subsequent infection and clinical disease in kittens (176, 177).  
Vaccination of kittens earlier than the recommended age of 9 weeks may be useful in 
high risk situations such as in breeding colonies.  In one study, a significant portion of six 
week old kittens with maternal antibodies responded to parenteral vaccination with a 
modified live vaccine (43).  In a separate study, vaccination of kittens with an intranasal 
vaccine at 5 weeks and a killed vaccine at 5 and 7 weeks also provided protection against 
disease in kittens with and without maternal antibodies, though seroconversion was 
delayed in kittens with maternal antibodies (89).  In some cases, kittens with maternal 
antibodies may become subclinically infected from the queen and become latent carriers 
of the virus (58).  
Diagnosis:  Identification of FHV-1 infection has been by detection of FHV-1 
antibodies by serum neutralization (178), enzyme linked immunosorbent assay (ELISA) 
(42, 191), or hemagglutination inhibition tests (63).  ELISA has been shown to be more 
sensitive than serum neutralization (42, 191) and hemagglutination inhibition tests (191).  
Diagnosis of FHV-1 by serology is problematic.  The magnitude of serum neutralization 
or ELISA titers is independent of the presence or absence of clinical signs of FHV-1 
associated disease, and seroprevalence does not differ between clinically normal cats or 
cats with acute respiratory disease or with chronic ocular disease.  Detection of serum 
 18
antibodies does not distinguish between infection by wild-type strain or attenuated 
vaccine strain.  Cats with chronic ocular disease have been shown to have lower serum 
ELISA titers than clinically normal cats.  Chronic or recrudescent infection, latency, prior 
infection, or vaccination may affect titers and limit the usefulness of paired serum 
samples for detection of active infection in chronically or latently infected cats (140).   
Diagnosis of FHV-1 infection is commonly done by detection of the virus.  Cats 
shed virus in ocular, nasal, and oropharyngeal secretions for at least 1-3 weeks during the 
initial infection, for several days during re-infection, and irregularly during periods of 
recrudescence (175).  Virus is detected by immunofluorescent antibody tests (28), virus 
isolation (38), or PCR (27, 72, 181, 214, 220, 237).  Virus may also be detected in tissues 
by immunohistochemistry and in situ hybridization (217). 
Virus isolation has been considered the gold standard for FHV-1 detection (160).  
Virus isolation and immunofluorescent antibody testing may be of limited value in 
diagnosing FHV-1 disease in cats with chronic conjunctivitis because cats shed less virus 
for a shorter period of time during periods of recrudescence or chronic disease (27), and 
virus isolation and immunofluorescent antibody tests have low sensitivity.  Positive 
results are more likely in cats with disease of shorter duration (159).  However, both tests 
can detect virus in clinically normal cats (27, 140).  In one study, virus isolation was 
found to be more sensitive than fluorescent antibody testing for detecting FHV-1 in cases 
of chronic conjunctivitis (159), but in a different study, the reverse was found in cats with 
chronic ocular disease (140).   
Problems exist with virus isolation and immunofluorescent antibody assays.  
Interpretation of immunofluorescent antibody assay results is subjective, and nonspecific 
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immunofluorescence can be falsely interpreted as positive.  Also, staining of the eye with 
a fluorescein dye to test for ulcers prior to collecting specimens for fluorescent antibody 
testing results in false-positive immunofluorescent antibody results (160).  False negative 
results may occur with low virus antigen or interference by host derived antibody (27).  
Virus isolation requires proper specimen handling to ensure presence of viable virus for 
this assay to be successful (140).   
There have been numerous PCR assays developed to detect FHV-1 DNA (27, 72, 
181, 214, 220, 237).  PCR assays have been determined to be more sensitive in detecting 
FHV-1 than virus isolation in latently infected cats (181), in cats with acute disease that 
have been previously vaccinated (220), and in cats with naturally acquired FHV-1 
infection with current signs of conjunctivitis or nasal discharge (27).  PCR may be more 
sensitive because as previously mentioned, virus isolation requires viable virus, and 
enveloped viruses are relatively labile and may be destroyed in transport and with 
freezing and thawing of samples.  In contrast, DNA is stable and transit time and 
temperature appear not to affect the ability to detect FHV-1 DNA in samples (30).  Virus 
infectivity may also be destroyed by enzymes in saliva or tears.  The virions may be 
complexed with antibodies, decreasing infectivity, which may explain the increased 
sensitivity of PCR in vaccinated cats or in cats with chronic disease.  Immature virions 
may also give positive PCR results but negative isolation results (181). 
Nested PCR has been determined to be more sensitive than single round PCR for 
detecting FHV-1 in cats with signs of upper respiratory tract disease (72).  Nested PCR is 
also more sensitive than virus isolation and fluorescent antibody detection (27, 214).    
 20
To increase the likelihood of detecting viral DNA in samples from cats with 
ocular disease, more than one specimen should be collected.  There appears to be no 
sampling technique (conjunctival or corneal swabs and scrapings, or biopsies of the 
conjunctiva or cornea) that is more likely than another to harvest viral DNA, except in 
cats with corneal sequestrum, in which no virus could be detected in swabs (232). 
Though more sensitive than isolation, different PCR protocols show marked 
variation in sensitivity, which affects the ability to detect FHV-1 DNA.  Six published 
PCR assays were compared to diagnose FHV-1, and detection rates varied from 29-86% 
in cats with keratits and/or conjunctivitis.  Each assay also detected five vaccines tested, 
suggesting a positive PCR result may be due to detecting a vaccine strain (137). 
      A more sensitive test may not necessarily be better due to the potential to 
increase detection of virus in subclinical shedders.  PCR results must be interpreted 
carefully, because a positive result may mean FHV-1 is the cause of the disease, found 
coincidentally as a result of intermittent shedding, or present secondary to stress caused 
by a separate disease that is primarily responsible for the clinical signs (27, 137).  
In one of the PCR studies, FHV-1 DNA was detected in samples from 31% of 
clinically normal shelter cats.  The author suggests PCR may be of limited value for 
diagnosing FHV-1 disease due to detection of healthy carriers (27).  In an additional 
study, FHV-1 DNA was also detected in 6/13 keratectomy specimens from clinically 
normal shelter cats (213), and in another study, FHV-1 DNA was detected in 45/92 
corneas from cats without a recent history of respiratory or ocular disease.  Twenty-nine 
of the positive samples were obtained from shelter cats.  The high rate of detection of 
FHV-1 DNA in normal corneal samples may represent detection of latent infection, 
 21
because the cornea may be a latently infected tissue, or may represent detection of 
subclinical shedders (224).  Each of these studies used shelter cats as the clinically 
healthy control groups, which may have exaggerated the problem of detecting subclinical 
shedders, because as previously mentioned, cats in that environment are at an increased 
risk of being exposed to the virus or having reactivated virus (27). 
Real time PCR assays have also been developed for detection of FHV-1 DNA and 
are more sensitive than virus isolation (74, 231).  Real time PCR and isolation results 
correlate well in the acute phase of the disease, but real time PCR is more likely to detect 
FHV-1 DNA in later phases of disease in which there is a marked decline of virus titer 
(231).  Real time PCR has an advantage over conventional PCR because of the ability to 
determine viral load and track the course of disease.  Real time PCR is also less prone to 
contamination than conventional PCR due to the lack of post-amplification processing 
(231).  This is especially true for nested PCR, in which contamination from the original 
product can arise (214). 
Antiviral drugs:  There are currently no anti-herpetic drugs approved for 
veterinary use in the United States, but many antiviral drugs marketed for treatment of 
herpes simplex virus type 1 infections in humans have been explored as therapeutic 
agents for treatment of FHV-1 infections in cats (136).  Several acyclic nucleoside 
analogs have been tested, including acyclovir, ganciclovir, and penciclovir (136, 157).  
These drugs work by incorporating into the viral DNA chain, terminating its growth and 
inactivating viral DNA synthesis.  Acyclic nucleoside analogs require three 
phosphorylation steps to be converted to their active form, and the first step is performed 
by the viral thymidine kinase, giving these drugs specificity for virally infected cells and 
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making them relatively safe (136).  Acyclovir is relatively ineffective against FHV-1 in 
vitro (136, 157, 228), but it appears to be effective in cats for treatment of FHV-1 related 
conjunctivitis and corneal ulcers if administered topically several times a day (244).  
Ganciclovir and penciclovir show greater efficacy than acyclovir in vitro, but in vivo 
studies have not been performed (136, 228).   
Other types of antiviral drugs have also been tested.  Ribavirin, an inhibitor of 
nucleic acid synthesis, has only a slight antiviral effect on FHV-1 and reduces the rate of 
cell proliferation in treated cultures (174).  Foscarnet, a drug that inhibits DNA 
polymerase by interacting with the pyrophosphate binding site of the enzyme, has 
intermediate to low antiviral efficacy in vitro (135, 228), but another viral DNA 
polymerase inhibitor, PMEDAP, has potent FHV-1 inhibition in vitro (228).  Cidofovir, a 
cytosine analog, has been shown to be effective against FHV-1 in both CRFK cells (136, 
228) and feline primary corneal cells (189).  Cidofovir does not require phosphorylation 
by the viral kinase, and it inhibits the viral DNA polymerase 1000 times more potently 
than it inhibits the host cell polymerase (136).  However, cidofovir causes increased cell 
death and decreased cell proliferation in corneal cells at effective antiviral doses (189).   
The antiviral drugs that have shown the greatest effectiveness in vitro include 
idoxuridine and trifluridine (135, 157).  These compounds also have non selective 
antiviral activity and inhibit CRFK cell proliferation at effective antiviral doses (157).  
The antivirals are epitheliotoxic and chronic use may lead to corneal or conjunctival 
disease (157), or may reduce cellular proliferation enough to negatively affect healing of 
corneal lesions (189).  An additional problem with the current antiviral drugs is that these 
drugs are virostatic and not virocidal.  Therefore, to be effective, these drugs must be 
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applied 4-6 times a day.  Idoxuridine, vidarabine, and trifluridine have been used 
clinically as topical treatments for ocular lesions, but one study suggests that the overall 
response to these treatments is poor.  This is possibly due in part to the need for frequent 
application of the drugs to be effective and poor owner compliance (212).      
There is currently no effective systemic antiviral drug available for use in cats 
(210).  Acyclovir is the only systemic drug that has been adequately tested and has been 
used clinically for treatment of FHV-1, but it has limited efficacy due to poor 
bioavailability and may also produce toxic side effects in cats (135, 167).  Because of the 
poor bioavailability of acyclovir, a pro-drug of acyclovir, valacyclovir, has been tested in 
cats.  After oral administration, valacyclovir is almost completely converted to acyclovir 
and provides much higher plasma concentrations of acyclovir than obtained with oral 
acyclovir administration.  Despite achieving effective doses in cats in the study, this drug 
did not suppress FHV-1 replication in the acutely infected cats and was found to be toxic, 
causing hepatic and renal necrosis and severe bone marrow suppression (154).  
Idoxuridine has also been tested systemically for treatment of FHV-1 in cats, and it 
produced vomiting, depression, and loss of appetite when administered intraperitoneally 
(208).  Therefore, any currently available systemic antiviral drug must be used with 
caution in cats (154).   
Adjunctive therapies:  There are also adjunctive therapies for chronic FHV-1 
infections.  Oral lysine supplementation is used clinically to treat FHV-1 infected cats.  
Oral L-lysine supplementation reduces the severity of conjunctivitis in cats undergoing 
primary infection (215), and reduces viral shedding in latently infected cats following 
changes in husbandry and housing but not following corticosteroid administration (141).  
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In vitro, reduction of FHV-1 replication by lysine supplementation only results with 
reduction of arginine concentrations.  Arginine exerts a substantial growth-promoting 
effect on FHV-1 and is an essential amino acid for viral protein synthesis, and it appears 
lysine antagonizes this effect.  Lysine and arginine competitively inhibit transport of each 
other by using a common transport system, and lysine induces arginase, an enzyme that 
causes the degradation of arginine.  Arginine deficiency inhibits synthesis of infectious 
viral particles and down regulates synthesis of viral proteins (138).   
Human recombinant interferon alpha has also been used as a treatment for FHV-
1.  Oral administration of low doses has been associated with reduced clinical signs but 
not reduced FHV-1 shedding (134).  The antiviral effect in vitro is modest (190) and dose 
dependent (198).  Interferon treatment may only be effective when administered in high 
doses early in the course of infection.  Human recombinant alpha-2b interferon is less 
effective against FHV-1 than feline recombinant omega interferon in vitro.  Interferon is 
probably most effective when administered as an adjunct treatment (198).  When used in 
combination with human recombinant interferon alpha, acyclovir could be used at a 
nearly eight fold reduction to achieve maximal inhibition of FHV-1 in vitro, and 
synergistic interactions were seen between the two treatments (239). 
Additional therapies that have been tested for FHV-1 infection include bovine 
lactoferrin and cat-mouse chimeric antibodies.  Bovine lactoferrin is a mammalian iron-
binding glycoprotein that is produced by mucosal epithelial cells and found in secretions 
including milk, colostrums, saliva, and tears.  It has antiviral, antibacterial, and 
antimycotic properties.  It appears to inhibit FHV-1 attachment or penetration into cells 
and has an inhibitory effect on FHV-1 replication in CRFK cells (12). 
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Mouse-cat chimeric antibodies targeting FHV-1 glycoprotein D have been used in 
two separate studies (226, 227).  In one study, the antibodies were administered 
intravenously to cats on day 2 post-infection with FHV-1.  The treated cats had decreased 
clinical signs compared to the control cats (226).  In the second study, the antibodies 
were used prophylactically, administered subcutaneously 15 days prior to infection with 
FHV-1, and resulted in decrease clinical signs in the treated group (227).  
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RNA Interference Literature Review 
Currently, there is no effective therapy that specifically targets FHV-1.  
Vaccination against FHV-1 provides only partial protection from clinical disease (195), 
and antivirals are minimally effective (212).  Therefore, the development of a therapy to 
specifically target this virus to decrease clinical signs associated with acute infections, to 
decrease establishment of latent infections, or to prevent recrudescence in latently 
infected cats to prevent viral shedding should be explored.  Such a therapy would be 
useful for cats in shelters, catteries, or multiple cat households, environments which are 
known to be associated with an increased risk for FHV-1 infection (75).   
Recently, RNA interference (RNAi) has been shown to be a possible therapeutic 
method for viral infections.  RNA interference therapy is sequence specific post-
transcriptional gene silencing based on an ancient self-defense mechanism conserved in 
many eukaryotic species (64). 
Discovery:  Silencing based on sequence homology was first discovered in 
transgenic plants and fungi.  In 1990, in a study in petunias, attempts to over-express 
endogenous genes by introduction of additional copies (transgenes) resulted in 
suppression of endogenous gene expression as well as the transgenes (152).  In a study in 
1993, infection by an RNA virus was shown to be restricted in plants by artificial 
expression of one of the viral genes, an observation apparently mediated by cytoplasmic 
activity that targets specific RNA for inactivation (119).  In 1996, quelling (transgene 
induced gene silencing) in Neurospora crassa, was determined to be mediated by an 
RNA molecule, and silencing was discovered to be associated with a decrease in 
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messenger RNA (mRNA) from the silenced gene (32).  The breakthrough discovery 
occurred in the nematode, Caenorhabditis elegans, in 1998, in which this process of post-
transcriptional silencing was linked with double-stranded RNA (dsRNA), and the process 
was named RNA interference (50). 
Cellular machinery and mechanism:  Introduction of dsRNA into cells can 
specifically lead to the degradation of mRNAs containing homologous sequences, 
resulting in gene silencing (50, 194).  RNA interference is initiated by a member of the 
RNase III family of ATP-dependent ribonucleases called Dicer, which binds with high 
affinity to double-stranded RNA and chops it into 21-23 nt. small interfering RNA 
(siRNA) duplexes, containing 19 base-pairs and 2 nucleotide 3’ overhangs (14, 48).  The 
siRNA duplexes, containing 3’ phosphates and 5’ hydroxyls, are incorporated into the 
RNA induced silencing complex (RISC) (71, 179).  For each duplex, one strand becomes 
the guide strand, and the other becomes the passenger strand.  The strand of the duplex 
that has the 5’ end less tightly bound to its complement becomes the guide strand (95, 
194).  The endonuclease component of RISC, Argonaute, cleaves the passenger strand, 
and it is removed from the complex, activating RISC, which contains the single-stranded 
guide (143, 179).  RISC then targets homologous mRNA transcripts by base pairing with 
the guide strand and cleaves the messenger RNA (performed by the Argonaute protein).  
The mRNA is cleaved between bases 10 and 11 relative to the 5’ end of the siRNA guide 
strand (48).  The mRNA is further degraded by exonucleases (70, 98). 
Amplification of the silencing signal and systemic spread of silencing occurs in 
plants and C. elegans, but this phenomenon has not yet been demonstrated in mammals 
(11).  In addition to the primary RNAi response, in which double stranded RNA interacts 
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with Dicer, resulting in 21-nt dsRNAs that interact with RISC to target complementary 
mRNA sequences, in plants and C. elegans, amplification of the trigger RNA occurs.  
The amplification contributes to the potency and persistence of RNAi in these organisms.  
Secondary siRNAs are produced in C. elegans and in the plant Arabidopsis by RNA 
dependent RNA polymerase (RdRP), which copies the mature mRNA template (11).  
These secondary siRNAs in C. elegans are 21-22 nt in length and have triphosphate 5’ 
termini, unlike primary siRNAs, which have a monophosphate at the 5’ end.  It is 
assumed in C. elegans that primary siRNAs act as guides to recruit the RdRP to the non-
degraded target transcript, resulting in the unprimed synthesis of short antisense RNAs, 
mainly upstream from the targeted sequence but also downstream, which are removed 
from the target transcript and incorporated into complexes capable of finding additional 
targets (168, 199).  Currently, there have not been any RdRP genes discovered in 
mammalian genomes (11). 
RNAi in mammalian cells and the interferon response:  Long dsRNAs activate 
RNAi in C. elegans (50) and in fruit flies, Drosophila melanogaster (71), but initial 
attempts to activate RNAi in mammalian cells with long dsRNAs failed.  dsRNA larger 
than 30 base pairs in the cytoplasm of mammalian cells can trigger the interferon 
response (47).  However, after the discovery that RNAs 21-22 nucleotides in length 
mediate RNA interference (48), the use of synthetic 21 nucleotide (nt) siRNAs was 
demonstrated to induce RNAi in mammalian cells without inducing interferon (47).   
Interferons are cytokines that function as the host’s first line of defense against 
viral infections and are part of the mammalian innate immune response.  Type 1 
interferons (alpha and beta) are produced in response to dsRNA (common viral 
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replication intermediates).  dsRNA binds and activates dsRNA-activated protein kinase 
PKR and 2’, 5’-oligoadenylate synthetase.  Activated PKR halts translation by 
phosphorylation of translation initiation factor eIF2α (eukaryotic initiation factor subunit 
α), resulting in a general inhibition of cellular protein synthesis.  Activated 2’-5’-
oligoadenylate synthetase causes mRNA degradation by activating RNase L in a non 
sequence specific manner (47).  Interferon alpha is primarily produced by leukocytes, and 
interferon beta is produced by fibroblasts and epithelial cells.  The role of interferon 
induction is to induce antiviral, antiproliferative, and immunomodulatory activities in 
cells (207). 
 RNAi as an antiviral defense mechanism:  RNAi is an innate antiviral defense 
mechanism in plants (39) and Drosophila (233).  The dsRNA develop as a result of 
replication intermediates or from secondary structure of viral RNA or from DNA viruses 
by annealing of overlapping complementary transcripts produced by symmetrical 
transcription (5).  An antiviral role for the RNAi machinery appears to also exist in C. 
elegans.  Though no natural virus of C. elegans is known, experimental infection with 
vesicular stomatitis virus results in resistance to the viral infection in the nematode (192, 
242).  It is unclear if RNAi is a natural defense mechanism against viruses in mammalian 
cells.  Because long dsRNA viral replication intermediates appear to be the natural 
precursors for siRNAs, and long dsRNA induces interferon and general shutdown of 
transcription in mammalian cells, it is unknown how this process may be naturally 
activated by viruses in mammalian cells (39, 64).  Mammals have also developed a 
highly sophisticated acquired immune system based on protein recognition that protects 
against infection in a highly specific manner (64). 
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miRNA pathway:  Naturally occurring siRNAs have not yet been detected in 
mammalian cells (64).  However, related small RNAs, called microRNAs (miRNA) have 
been discovered in mammalian cells (108, 112).  miRNAs result from endogenous non-
coding genes distinct from the mRNA they control or come from introns of pre-mRNAs 
(10).  miRNAs were first discovered in C. elegans (108, 112), and have also been 
identified in fish, worms, flies, and plants and are generally conserved.  miRNAs are 
expressed during developmental stages and in a tissue specific manner and have 
important regulatory roles for development and differentiation in plants and animals (10).  
Long primary transcripts (pri-miRNA) are cleaved by an RNase III endonuclease, 
Drosha, in the nucleus, resulting in 60-70 nucleotide stem loop precursors (pre-miRNA).  
The pre-miRNAs are transported from the nucleus by the export factor, Exportin-5.  In 
the cytoplasm, the pre-miRNAs are processed by Dicer into approximately 22 
nucleotides.  miRNAs are then incorporated into RISC and regulate mRNA expression by 
either target destruction or translation inhibition.  Partially complementary sequences, 
predominately in the 3’ untranslated region of the target, result in blockage of translation.  
Complementary results in destruction of the target by RISC, which mainly occurs in 
plants (10).  Apparently siRNAs and miRNAs program RISC equivalently and can have 
the same effects on mRNA expression, despite different origins (251). 
RNAi in human cells likely results from incorporation of siRNAs into the miRNA 
pathway (70).  While Drosophila has two Dicer proteins, humans have only one Dicer 
protein.  In Drosophila, miRNA and siRNA pathways use separate Dicer proteins.  The 
Dicer protein in human cells resembles the DICER-1 protein in Drosophila, essential for 
miRNA processing.  Also, the Argonaute proteins of mammalian cells are related to 
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Drosophila Ago1, which preferentially binds miRNAs.  Mammalian cells lack a homolog 
of Drosophila Ago2, which preferentially binds siRNAs and protects Drosophila from 
infection with RNA viruses (52, 70).  This suggests the human genome has retained the 
miRNA processing machinery, but not the specific machinery for processing long 
double-stranded RNAs (70).   
Viral suppressors of RNAi:  If RNAi is a natural defense mechanism against 
viruses in mammals, then viral infection should result in the production of siRNAs of 
viral origin, but as previously stated, no naturally occurring siRNAs have been identified 
in mammalian cells.  Also, inhibition of RNAi should result in increased viral replication, 
and as an adaptive response, the viruses should have developed proteins that inhibit the 
RNAi response.  Each of these criteria has been demonstrated in plants, in which RNAi is 
an important viral defense mechanism.  In an attempt to prove RNAi is a naturally 
occurring process in mammalian cells, recent studies have attempted to identify RNAi 
suppressors in mammalian viruses.  In nature, the best examples of viral suppressors of 
RNA interference are found in plant viruses (39). 
RNAi suppressor dsRNA binding appears to be a key element in the silencing 
suppression strategy that has evolved independently many times.  Many unrelated plant 
RNA virus RNAi suppressors bind dsRNA.  Many of these suppressors are size selective, 
preferentially binding 21 nucleotide dsRNA.  This is the fragment size generated by 
Dicer, so expression of a protein that binds these RNAs, preventing their incorporation 
into RISC to form active silencing effecter complexes, is an ideal viral defense strategy.  
This may also be true for invertebrate virus RNAi suppressors, such as the flock house 
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virus B2 suppressor, also a double stranded RNA binding protein, which could 
potentially inhibit viral suppression by RNAi in C. elegans (144). 
dsRNA binding proteins have been the target of investigation for potential human 
virus silencers of RNAi.  Two such proteins, the non-structural (NS1) protein of 
influenza A and the E3L protein of vaccinia have been shown to suppress RNAi in 
experiments in Drosophila cells (115).  NS1 was shown to bind siRNAs in a plant 
experiment, suggesting it suppresses RNAi by sequestering siRNAs, a mechanism which 
occurs in many plants (25).   But it has been discovered that influenza NS1 does not 
suppress RNAi in mammalian cells, though it does inhibit the interferon response (100).  
Both NS1 and E3L are important for the pathogenesis of these viruses in the natural host 
because they function as inhibitors of the innate antiviral response regulated by 
interferon.  So the suppression of RNAi by these proteins is likely due to their over-
expression in cells not naturally infected with these viruses and to their ability to bind 
dsRNA (39).  Interestingly, a size specific dsRNA binding virus silencing suppressor has 
not yet been identified in animals (144). 
A suppressor of RNAi has also been proposed for HIV-1.  The gene Tat encodes 
an activator of the HIV-1 LTR, and according to some researchers, Tat inhibits Dicer.  
Therefore, siRNAs cannot be produced and viral RNAs are not targeted (13).  However, 
Tat can also act as a nonspecific dsRNA binding protein and the observed effect is 
probably due to the massive over-expression of the protein.  At physiological 
concentrations, the protein shows no inhibition of RNAi (39).   
Human adenovirus type 5 encodes two non-translated RNA polymerase III 
transcripts, which act as decoy RNA to prevent the induction of the interferon system in 
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infected cells.  The virus associated (VA) RNAs also appear to inhibit RNAi by acting as 
competitive substrates for Dicer and are processed into 21nt dsRNAs that are 
incorporated into RISC.  These siRNAs may act more like miRNAs to suppress viral or 
cellular gene expression during infection (5).  VA1 was also shown to compete with 
cellular pre-miRNAs for transport from the nucleus by the factor Exportin-5 (121).  VA1 
RNA is highly expressed during viral infection, so the inhibitory effect of this RNA could 
be inadvertent.  Its activity as an RNAi inhibitor may be coincidental based on its 
structure, which resembles pre-microRNAs.  It is unknown if VA RNA specifically 
evolved to function as an RNAi inhibitor (39). 
Cellular miRNA may have a role in antiviral defense in mammalian cells.  Human 
miR-32 inhibits primate foamy virus type 1 in human cells as the result of “fortuitous” 
near perfect sequence homology between a portion of the virus sequence and the cellular 
miRNA.  The homology is adequate enough to produce virus translation inhibition.  Also, 
the virus produces a protein, Tas, that inhibits the miR-32 translational inhibition, in a 
non-sequence specific manner (110).  However, it remains unclear whether Tas does 
indeed act as an RNAi suppressor in primate foamy virus infected cells (39). 
Experimentally induced antiviral RNAi in mammalian cells:  The RNAi 
machinery likely exists in vertebrates only for post-transcriptional regulation by genome 
encoded miRNA.  Despite this fact, the machinery can be reprogrammed for antiviral 
immunity by the introduction of exogenous RNA to generate an artificial RNAi response 
(39).  Numerous experiments demonstrate that exogenous siRNAs can prevent in vitro 
and in vivo infections with many different viruses, including positive and negative 
stranded RNA viruses, retroviruses, and DNA viruses (64). 
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RNA silencing could be used to complement the protein-based immune response 
to viruses.  RNAi occurs in the cytoplasm of cells, where recognition of virus by B and T 
lymphocytes cannot take place.  The RNAi response is rapid, taking only hours to exert 
its effect; whereas, the immune response, even the anamnestic response, takes days (29).  
In cases in which virus causes severe acute disease due to significant cytopathic effect 
resulting from high multiplicity of infection, low immunogenicity, high replication 
capacity, direct toxic effects, or a combination of each, RNAi could support or enhance 
the antiviral effects for a short period of time until innate or adaptive immune responses 
allow the host to overcome the pathogen (94). 
Incoming positive-stranded viral RNA may be targeted by RNAi, as is the case 
for West Nile virus (62) and hepatitis C virus (247).  These viruses initially act as mRNA 
after infecting cells, and the viral target of the RNAi machinery is likely the mRNA 
(strand that directs protein synthesis) and not viral genomic RNAs (strands acting as 
templates for replication) (7, 18, 61).  This is demonstrated by the superiority of RNAi 
targeting the positive-strand of a positive single-stranded RNA virus, versus targeting the 
negative strand replication intermediate (193).  Genomic strands kept inside specialized 
compartments in the cell cytoplasm, such as occurs with rotavirus (7) and West Nile virus 
(62), are likely inaccessible to the RNAi machinery. 
Various phases of the life cycle of viruses have been targeted by RNA 
interference.  Targeting viral transcription factors, such as E6 in the human 
papillomavirus, results in an inhibition of viral gene expression and inhibited growth in 
culture (94).  Targeting a portion of the influenza RNA transcriptase effectively inhibits 
production of all viral mRNAs (61).  Targeting the 5’ untranslated region of hepatitis C 
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virus, which has an internal ribosomal entry site for translation of the entire viral 
polyprotein, inhibits protein synthesis.  Blocking synthesis of non-structural proteins 
required for replication of subgenomic viral RNA results in suppression of viral infection 
(250). 
Inhibiting viral replication is likely the best method of suppressing viral infection 
(94).  In many studies, the RNA dependent RNA polymerase of RNA viruses, including 
SARS (234), West Nile virus (164), and coxsackievirus B3/picornavirus (193) has been 
targeted to inhibit viral infection.  Virus encoded DNA polymerase is also an effective 
target for inhibiting viral replication of DNA viruses such as herpesviruses (241).  Also, 
silencing of the nucleocapsid gene, which produces a protein necessary for genome RNA 
replication, has been shown to inhibit influenza replication in vitro and in embryonated 
chicken eggs (61). 
Attachment proteins have also been targeted effectively, including the spike 
protein of SARS (2), and the envelope glycoprotein B of herpes simplex virus type 2 
(169).  Silencing the attachment protein VP4 of rotavirus has been shown to be effective 
in reducing infectious viral progeny, whereas all other structural proteins were unaltered 
(45). 
Also, RNAi can be used to target genes whose products are involved in assembly 
and budding of the virus particle from the plasma membrane.  In a study with the Sendai 
virus, a member of the Paramyxoviridae family, targeting of the matrix protein resulted 
in reduction of virus production, but had no effect on viral replication or transcription 
(149).  Knockdown of viral genes used in late stages of the intercellular viral life cycle, 
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such as for viral assembly, is expected to be less effective than RNAi in early steps of the 
viral life cycle (94). 
Down regulation of cellular factors associated with viral infections has proven 
effective for inhibiting replication of HIV-1.  However, many molecules are essential for 
normal cell processes and are inappropriate targets (94). 
Methods of siRNA delivery into cells:  Effective therapeutic use of siRNAs 
involves the development of delivery systems that stabilize the siRNAs but not interfere 
with their gene silencing activity, provide efficient delivery to the target organs, and 
maintain a siRNA half life sufficient enough to be therapeutic (1).  Currently, cationic 
lipids and polymers are commonly used to transfect cells in vitro.  However, problems 
associated with these methods include lack of transfection efficiency and toxicity.  A 
commonly used transfection reagent, Lipofectamine 2000, by itself and complexed with 
siRNAs is toxic to cells at the doses required for optimal transfection, and use of high 
concentrations of siRNA results in cellular detachment (203).  However, lipid 
transfecting reagents have been used successfully in in vivo studies (169) (19). 
Polyethylenimine (PEI), a synthetic polymer containing a high cationic charge, 
has been used in many studies.  PEI is able to complex negatively charged siRNAs, 
forming colloidal particles which are endocytosed by the cell.  The buffering capacity of 
PEI protects the siRNAs from destruction within the endosomes and the effects of the 
PEI result in osmotic swelling and disruption of the endosomes, with release of the 
complexes (1).  PEI has been effectively used to deliver influenza virus gene specific 
siRNAs into lung cells by intravenous administration for therapeutic/prophylactic 
treatment of influenza in mice (60).  But in other studies, PEI used intranasally resulted in 
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sickness and death in mice (19), and when used intratracheally or intravenously, resulted 
in severe lung inflammation in mice (114). 
Additional methods of delivery to increase transfection efficiency have been 
studied, including using cell-penetrating peptides, which interact with negatively charged 
particles on the cell surface and appear to be taken into the cell by endocytosis.  The 
problem with transfection efficiency may not be inefficient uptake of molecules, but the 
lack of release of bioavailable siRNA molecules from endocytosed vesicles (230). 
Early in vivo studies used hydrodynamic intravenous injection to force siRNAs 
into cells.  However, this is impractical for use in humans, because it may cause transient 
right sided heart failure and liver damage by requiring injection of a bolus of liquid 
equivalent to 3 liters (59).  Transfection is good for local delivery of siRNAs, especially 
for delivery to mucosal surfaces (19, 169).  In fact, local delivery of naked siRNAs in cell 
culture medium (19) or in a dextrose solution (114) into the nasal cavity has been 
successful for prevention/treatment of respiratory syncytial virus (RSV) in mice and 
SARS in macaques.  Currently, siRNAs delivered by aerosol administration are being 
used in a phase I clinical trial for RSV (98).  However, systemic delivery is more of a 
challenge.  Ideally, the goal is to deliver siRNAs into specific cells to decrease the 
amount of drug necessary for therapeutic effect and avoid nonspecific silencing in 
bystander cells.  A method for targeted delivery is antibody mediated delivery.  The Fab 
fragment directed against the HIV-1 envelope protein gp160, fused to siRNAs, has been 
used to deliver siRNAs specifically to cells expressing the HIV-1 envelope protein.  This 
method was successful for targeted delivery both in vitro, and in vivo, when injected 
intravenously in mice (202). 
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Down regulation of target genes with siRNAs is transient because intracellular 
concentrations are diluted over consecutive cell divisions (98).  The effect lasts only 3-5 
days in cell culture.  This duration of silencing is acceptable for acute infections such as 
SARS and influenza, but not for chronic infections such as HIV and hepatitis C (94).  
Silencing can be enhanced by consecutive applications of siRNAs to virus infected cells; 
however, this can lead to selection of mutants that have changes in the target region 
(247), especially in chronic infections with RNA viruses that produce quasispecies 
populations (104). 
Stable expression of RNA effector molecules is possible with plasmids or viral 
vectors.  The most common approach uses short hairpin RNAs (shRNAs), which are 
generated from DNA vectors that express the short hairpin structures, resembling pre-
miRNA, from RNA polymerase III promoters (4, 24).  Polymerase II promoters have also 
been used to produce shRNAs that mimic pri-miRNAs (98).  The short hairpin structures 
are processed into siRNAs by Dicer (24).  In Drosophila, Dicer has been shown to be 
instrumental in handing over the 21 nucleotide duplexes to RISC, and Dicer substrates, 
such as shRNAs, are more potent inducers of RNAi than 21mer siRNAs (4).  The 
shRNAs are incorporated into the miRNA pathway, and over expression of shRNAs in 
vivo can be fatal.  In one study, shRNAs expressed from a viral vector in mouse liver 
cells resulted in liver failure and death in the mice.  There was associated down 
regulation of liver miRNAs, presumably due to the competition of the cellular miRNAs 
with the shRNAs for cellular components of the miRNA pathway, including the nuclear 
factor exportin-5 (68). 
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Dicer substrates incorporated into the miRNA pathway beyond the nuclear 
processing stages may potentially be safer for use in vivo.  Recently, longer siRNAs, 27-
mers, were also shown to be more potent inducers of RNAi.  These longer siRNAs are 
processed by Dicer and therefore, the resultant siRNAs are more efficiently incorporated 
into RISC (96). 
Viral vectors, such as lentivirus or adenovirus vectors, have been used extensively 
in vitro to deliver shRNA plasmids into cells for long term expression of RNA effector 
molecules.  These vectors are currently the best vehicles for effective transfer of genetic 
material into cells (223).  Problems with viral vectors used in the past in vivo for gene 
therapy have included a massive immune response to an adenoviral vector that had 
disseminated into the circulation of a patient, and oncogenesis (leukemia) in patients by a 
retrovirus vector that inserted in or near an oncogene.  However, improvements have 
been made in these viral vectors (223).  In fact, in an upcoming clinical trial, a lentiviral 
vector will be used to deliver a shRNA targeting HIV-1 into hematopoetic stem cells ex 
vivo as part of a combinatorial RNA therapy for HIV-1 infection (98). 
Toxicity associated with experimental RNAi:  Design of siRNAs may be more 
important for effective targeting than the method of delivery.  The thermodynamic 
properties of siRNA molecules are critical to the functionality of the molecules.  These 
properties facilitate association with RISC and subsequent degradation of target mRNA 
(95). 
siRNAs must be designed to prevent off-target effects, which are toxic to the cell.  
Off-target effects associated with synthetic siRNAs have been shown to be concentration 
dependent, with increased concentrations of siRNA leading to a stress response within 
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the cell.  The effects may include stimulation and suppression of expression of genes 
unrelated to the intended target (171, 196). These effects appear to be sequence-related; 
siRNAs may cross-react with mRNAs of limited sequence homogeneity.  As few as 11 
contiguous nucleotides of sequence homogeneity, specifically located in the 5’ end of the 
antisense strand, are capable of cross-hybridizing to transcripts of non-targeted genes, 
resulting in their silencing.  Both the sense and antisense strands are capable of causing 
off-target effects (83).  Thus, siRNAs should be designed to direct the antisense strand 
(mRNA complement) into RISC (85).  In a more recent study, off-target effects were 
shown to result from homology between sequences of 7-8 nucleotides in the 5’ end of the 
antisense strand and the 3’ untranslated region of the unintended mRNA targets.  Thus, 
the off-target silencing occurs in a manner similar to silencing by miRNAs (84).  
Scrambled siRNAs used as controls may translationally suppress untargeted genes by 
forming bulging loops and initiate the miRNA mechanism.  In functioning like miRNAs 
with partial homology, mRNA levels of off-target genes may be unaffected, but protein 
expression is decreased (84).  Considering as few as seven nucleotides of homogeneity 
are all that is necessary to potentially produce off-target effects, specificity in siRNA 
design is difficult to achieve, and it is unlikely that all off-target effects can be prevented 
(84).  Therefore, observing the same phenotype with multiple individual siRNAs 
targeting the same gene increases the confidence that the knockdown of the intended 
gene can be attributed to the observed phenotype (84, 85). 
Toxicity may also be due to activation of the innate immune response by siRNAs.  
Long dsRNA is detected in vertebrate cells by the dsRNA-activated protein kinase PKR 
and by Toll-like receptor 3.  Therefore, as previously mentioned, long dsRNAs cannot be 
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used as triggers for the RNAi response in mammalian cells, but short siRNAs can be used 
successfully (47).  However, production of siRNAs with a bacteriophage T7 RNA 
polymerase induces a type 1 interferon response.  The response has been shown to result 
from a 5’ triphosphate on the siRNAs, which is used by the polymerase to initiate 
transcription (97).  shRNA plasmid vectors have also been shown to trigger an interferon 
response.  The authors suggest the response may be due to the accumulation of 
unprocessed polymerase III transcripts that trigger interferon expression, so the lowest 
effective dose of vector must be used to alleviate the problem (23). 
Therefore, chemically synthesized siRNAs represent the gold standard for RNAi 
applications (4).  However, one report suggests 21 nucleotide dsRNAs (including 
chemically produced siRNAs) transfected into cells can activate PKR in a concentration 
dependent manner, resulting in interferon beta production and nonspecific suppression in 
cells (200).  A different study suggests siRNAs mediate a type 1 interferon response by 
binding Toll-like receptor 3, which recognizes dsRNA and induces interferon (93).  
However, use of naked siRNAs in vivo is not associated with much of an interferon 
response, but when coupled with cationic lipids, a marked interferon (type I and II) 
response can be generated (122).  In two additional studies, siRNAs delivered by lipid 
transfection reagents induced production of interferon alpha in plasmacytoid dendritic 
cells in vitro and production of interferon alpha and cytokines, IL-6 and TNFα, with 
activation of T cells and dendritic cells in the spleens of mice (81, 91).  It appears siRNA 
activation of the innate immune response is dependent on the use of delivery vehicles and 
the recognition of the siRNAs occurs within the endosomal pathway by toll-like receptor 
7, which is located in the endosomal membrane and recognizes single-stranded RNA 
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(81).  Therefore, PKR and Toll-like receptor 3, binders of long dsRNA, likely do not 
represent the major mechanisms by which siRNAs are detected by the innate immune 
system (81).  The activation of Toll-like receptor 7 is dose dependent and sequence 
dependent.  Poly (U) or GU rich sequences can be immunostimulatory, and siRNAs 
containing a UGUGU motif or a GUCCUUCAA motif have been determined to activate 
the innate immune response (81, 91).  Therefore, testing for interferon induction is 
important before attributing knockdown of gene expression to RNAi in mammalian cells 
(23). 
 siRNA design:  Many siRNA design criteria have been developed to increase the 
effectiveness of individual siRNAs and to augment the production of toxicity due to off-
target effects, activation of the innate interferon response, or some nonspecific effect.  
The most important criterion appears to be asymmetry in the stability of the duplex ends.  
The 5’ end of the antisense strand should be less thermodynamically stable than the 3’ 
end (3, 182)  This facilitates the use of the antisense strand as the guide strand by RISC 
(95, 194).  The A/U differential of the 3 terminal base pairs at either end of the duplex is 
important for this asymmetry (3).  The 5’ end of the antisense strand should be A/U rich, 
especially the first five nucleotides (182, 225).  According to evaluations of siRNAs, 
functional siRNAs (defined as producing 70% or greater knockdown of the intended 
mRNA target (3)) have an A/U at position 1 of the antisense strand, but no G/C, and have 
a G/C at position 19 of the antisense strand, but no U (3, 182, 225).  Other single 
nucleotide bases associated with effective silencing include an A at positions 17 and 14, a 
U at position 10, and no G at position 7 of the antisense strand (3, 182).  Additional 
recommendations include, a G/C content of approximately 30-53% (3, 182), with absence 
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of a long G/C stretch of more than 9 nt in length (225), a low melting temperature, and 
lack of inverted repeats which would lead to hairpin structures in the antisense strand 
(182).  The 3’ overhangs have little to no effect on the activity (3).  Despite using rational 
design rules, it is still difficult to predict if a particular siRNA will work.  It is expect 
about 1 out of every 3 siRNAs will give highly effective silencing (66), and some siRNA 
that should not work according to the design rules are sometimes the most effective (19). 
 Viral RNAi escape mechanisms:  The mRNA secondary structure also 
determines siRNA silencing efficiency (103, 240).  This was demonstrated in an HIV 
study in which a point mutation outside the siRNA target sequence resulted in changes in 
the secondary structure of the mRNA.  The mutation caused the target sequence to be 
incorporated into a hairpin structure, thereby inhibiting its ability to base-pair with the 
siRNA, resulting in escape from RNAi (240). 
As previously mentioned, viruses can also escape destruction by experimentally 
induced RNAi by developing mutations in the target region.  These escape mutants have 
been described in RNAi experiments with viruses including Polio (65), HIV (40), and 
hepatitis C (247), appearing in cell culture after a few weeks.  One single nucleotide 
substitution in the central target region has been associated with interference escape (65, 
104).  Deletion (partial or complete) of the target region has been shown in HIV 
experiments, as well as accumulation of several point mutations (40).  It has been 
suggested that in some cases, a single point mutation increases the level of resistance of 
the virus, allowing further selective pressure to accumulate more point mutations, with 
successive increases in the level of resistance (247).  The difference observed in the level 
of resistance conferred by point mutations is associated with the location of the mutation 
 44
in the target sequence.  Complete homology within the central region of the targeted 
sequence is essential for silencing and substitutions at a few positions within the 3’ and 5’ 
ends of the target sequence are only partially tolerated (187).  Nucleotides 2-8 in the 
guide strand (antisense strand) are important for target recognition (seed region).  The 
first nucleotide does not contribute to target recognition; instead, it is sequestered in the 
binding pocket of the endonuclease domain of the Argonaute protein.  Nucleotides 9 
through the 3’ terminal end have reduced importance for target recognition (70). 
Targeting conserved sequences in essential viral genes is unlikely to result in 
deletion of the target sequence as an escape mechanism.  This would not likely be 
maintained because it would not be consistent with life of the virus.  Silent mutations are 
more likely to occur, leading to changes in nucleotides but not amino acids (40).  
Mutational associated escape is more likely to occur with RNA viruses, which lack 
proofreading capability in the RNA polymerase (247).  The viruses least likely to escape 
RNAi are DNA viruses due to lower mutation frequencies (64).  Development of escape 
mutants has been shown to be prevented or decreased by using a combination of siRNAs 
targeting different parts of the viral genome (247).  Targeting multiple genes has been 
shown to be more effective than targeting a single gene (169).  However, with use of 
multiple siRNAs, the RNAi machinery can become saturated, with no enhanced effect 
(94) or result in degradation of untargeted genes (105). 
Feline herpesvirus 1 is a suitable virus for targeting by RNAi.  The virus, in the 
vast majority of cases, produces a localized respiratory infection (37).  Therefore, no 
systemic administration of siRNAs is necessary, eliminating the challenge of targeted 
delivery.  In vivo studies have already demonstrated the effective uptake of siRNAs from 
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mucosal surfaces (169), including effective intranasal delivery of siRNAs for treatment of 
respiratory viruses (19, 114).  FHV-1 is a DNA virus and due to lower mutation 
frequencies of DNA viruses, escape mutation is not expected to be a significant problem 
(64).  Targeting conserved regions in essential genes is also less likely to lead to 
mutational escape, and in targeting these genes, replication of the virus can be inhibited 
(169).  Targeting conserved regions also mitigates the problem of sequence diversity 
between viral isolates (169).  Fortunately, FHV-1 has an apparently low rate of genetic 
variability between isolates (67).  Previous studies have shown that targeting essential 
genes in herpesviruses, including a herpesvirus DNA polymerase gene (241) and 
glycoprotein B, an attachment protein gene (169), can effectively inhibit herpesvirus 
replication.  The glycoproteins that are essential for FHV-1 attachment and cell 
penetration have not yet been determined, but the essential herpes simplex virus 
glycoproteins are gD, gB, and gH-gL (162). 
FHV-1 glycoprotein D and viral DNA polymerase genes were chosen as targets for 
silencing for this study.  FHV-1 glycoprotein D, an envelope protein, is the viral 
hemagglutinin and an important contributor to viral infectivity.  This glycoprotein is an 
inducer of virus-neutralizing antibodies (125, 128).   This gene also appears to be highly 
conserved (243).  FHV-1 glycoprotein D may play an important role in the restriction of 
the host range of the virus to feline cells (131).  In the related virus, herpes simplex virus 
type 1, glycoprotein D is necessary for penetration of the virus into cells (116).  It is an 
essential receptor-binding polypeptide, binding to herpesvirus entry mediator A and 
nectin-1 receptors on human cells (102).  Therefore, like the DNA polymerase gene, 
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FHV-1 glycoprotein D is expected to be essential for viral replication in feline cells.  The 
hypotheses for this study are as follows: 
1.   FHV DNA polymerase and gD genes are essential for FHV growth in vitro. 
2. Silencing of either gene through mRNA destruction by RNA interference will 
result in decreased viral infection in Crandell-Reese feline kidney cells. 
3. Decreased viral infection will result in decreased viral titer, decreased viral 
mRNAs, and decreased viral proteins. 
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Abstract 
Feline herpesvirus 1 (FHV-1) is an alphaherpesvirus and produces the most 
severe upper respiratory disease of cats.  Symptoms include an ocular infection that 
resembles the infection produced by the related virus, herpes simplex virus type 1, in 
humans.  Like all alphaherpesviruses, FHV-1 produces latent infections, and this virus is 
widespread in the feline population.  Vaccines are available but do not prevent infection 
and antivirals are only minimally effective for treatment of chronic ocular infections in 
cats.  We evaluated RNA interference as a method to prevent FHV-1 infection in vitro.  
Two siRNAs designed to target the viral DNA polymerase were effective in suppressing 
viral replication.  Therefore, RNA interference has potential as an antiviral therapeutic for 
FHV-1 and this study lays the groundwork for potential in vivo investigations in cats. 
Introduction 
Feline herpesvirus 1 (FHV-1) is a member of the subfamily Alphaherpesvirinae  
and consists of a single linear molecule of double-stranded DNA (31).  FHV-1 is wide-
spread in the feline population, with as many as 71% of cats seropositive for this virus 
(20), and it causes 50% of the cases of upper respiratory disease in cats (23).  Of these 
infections, FHV-1 causes the most severe clinical disease (30).  Acute infections are 
usually localized to the respiratory tract, and clinical signs include pyrexia, ocular and 
nasal discharge, rhinitis, tracheitis, and depression (7, 22).  Primary ocular infection, as 
occurs in humans with the related virus, herpes simplex virus type 1, consistently 
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produces conjunctivitis and minimal corneal involvement.  Acute signs, though 
potentially severe, usually resolve in a few weeks (30). 
FHV-1 is very fragile in nature and does not survive long outside the host, so 
transmission requires close contact, especially mucosal contact, and sneezing and short 
distance droplet spread are important in transmission in large confined populations, such 
as in breeding colonies and rescue catteries (25).  Upper respiratory infections in cats is 
second only to overcrowding as the leading cause of euthanasia in shelters, and FHV-1 is 
one of the most important causes of shelter respiratory disease (3). 
FHV-1  has been perpetuated in nature as a result of its ability to produce latent 
infections, and latently infected cats represent the most important reservoir of the virus 
(11, 24).  Approximately 80% of cats infected with the virus become latently infected 
(11).  During periods of stress such as changes in housing, parturition and lactation, or 
with corticosteroid administration, recrudescence occurs with associated viral shedding, 
with or without clinical disease.  Also, 29% of latently infected cats are spontaneous 
shedders.(11)  Though the majority of latently infected cats do not develop chronic 
clinical disease (1), there is still a large percentage of adult cats that have this problem 
(34).  The clinical manifestations of disease due to repeated recrudescence, including 
corneal ulcerations (4), eosinophilic keratitis, or corneal sequestration (26), are 
significant and can potentially lead to blindness (1). 
Antiviral medications approved for treatment of herpes simplex virus type 1 in 
humans are only minimally effective for treatment of these chronic cases in cats (35).  
This is possibly due in part to the need for frequent application of the virostatic drugs to 
be effective and poor owner compliance (35).  Vaccines are available for FHV-1, but 
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because the virus is poorly immunogenic (2), the vaccines do not prevent infection or 
shedding and only produce partial protection from clinical disease (6).  Therefore, 
development of a new therapeutic for FHV-1 would be beneficial.   
Recently, a mechanism called RNA interference (RNAi) has been manipulated for 
prevention of various mammalian viral infections both in vitro and in vivo (18).  RNA 
interference is a double stranded RNA-guided gene silencing pathway that is found in a 
variety of eukaryotic organisms, including yeast, plants, and mammals (for a review, see 
reference (14).  The double stranded RNA, small interfering RNAs (siRNA), that triggers 
the pathway can be supplied exogenously to silence specific genes (10, 14). 
The best method of suppressing viral infection is inhibiting viral replication (17).  
Previous studies have shown that targeting essential genes in herpesviruses, including a 
herpesvirus DNA polymerase gene (37), can effectively inhibit herpesvirus replication.  
We have shown that siRNA designed to specifically target DNA polymerase gene 
expression of FHV-1 can significantly reduce viral replication in vitro, and this gene is an 
excellent target for antiviral therapy. 
Materials and Methods 
Cells and viruses:  Crandell-Reese feline kidney (CRFK) cells (ATCC, Manassas, 
VA) were propagated and maintained in Dulbecco’s minimal essential medium (DMEM) 
(Cambrex, Charles City, IA) supplemented with heat-inactivated 5% fetal bovine serum 
(Atlanta Biologicals, Lawrenceville, GA), 100 U/ml penicillin, 100µg/ml streptomycin, 
and Fungizone (Cambrex) at 37˚C in a 5% CO2 incubator.  The prototype FHV-1 strain 
C-27 (ATCC) was used for the study.  A calicivirus wild-type strain used in the study and 
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10 FHV-1 isolates from 2003-2006 were a generous gift from the Clinical Virology 
Laboratory, University of Tennessee, Knoxville, TN. 
siRNAs and transfection:  Five siRNAs designed to target the DNA polymerase 
mRNA of FHV-1 were produced by Ambion- Applied Biosystems (Austin, TX) (Table 
2.1).  The FHV-1 sequences targeted by the siRNAs are identical in each of the FHV-1 
DNA polymerase sequences contained in GenBank and in an additional 10 isolates 
obtained from cats from 2003-2006.  Transfections of 100 nM siRNA per well in six well 
plates were performed with 5 µL of Lipofectamine 2000 (Invitrogen, Carlsbad, CA) per 
sample using Opti-MEM (Gibco-Invitrogen), according to manufacturer’s protocol.  
Approximately 5 x 104 CRFK cells diluted in DMEM supplemented with 10% FBS were 
added to each well containing the transfection mixtures.  Plates were incubated for 24 
hours prior to infection with FHV-1.  Each siRNA was tested in duplicate, and functional 
siRNAs were retested for a total of three experiments per siRNA.  A non-targeting 
negative control siRNA was purchased from Ambion.  siRNAs targeting the feline 
GAPDH gene, also obtained from Ambion, were used as a positive control to verify 
effective siRNA transfection (Table 2.1).  Other controls used for each experiment 
included uninfected/mock-transfected CRFK cells, FHV-1 infected/non-transfected cells, 
and a type 1 interferon control.  The type 1 interferon control consisted of non-transfected 
CRFK cells infected with feline calicivirus, an RNA virus that activates interferon β in 
CRFK cells.  
Virus infection and plaque assays:  The FHV-1 strain C-27 (ATCC) was grown 
in CRFK cells until 50% cytopathic effect was visible.  Plaque forming units were  
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TABLE 2.1  siRNA designed to target mRNA. 
 






































a. Upper case letters represent guide sequence, lower case letters represent 3’ overhangs 
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determined by plaque assay as previously described (8).  However, instead of using an 
agarose overlay, serum from a cat with an IFA titer of >1:2560 (a gift from the University 
of Tennessee Clinical Virology Lab) was used at a dilution of 1:50.  Aliquots of virus 
were prepared and frozen at -80ºC, and each aliquot was used only once for each 
experiment. 
Transfected CRFK cells were infected with FHV-1 at a MOI of 0.1.  One hour 
after incubation, the cells were washed with DMEM and fresh DMEM supplemented 
with 10% FBS was added to each well.  Infected cells were incubated for a total of 48 
hours.  500 µL of cell culture medium was removed from each well at 48 hours and 
stored at -80˚C until plaque assays could be performed.  
 Flow Cytometry:  Forty-eight hours after infection, the cells in each test and 
control well were trypsinized, washed with phosphate-buffered saline (PBS) (Gibco- 
Invitrogen), and resuspended in 1 mL of PBS per sample.  100µL of each suspension was 
removed and placed on ice for later RNA extraction.  An additional 100 µL of each 
suspension was removed and processed for Western blot analysis, and the rest of each 
sample was processed for flow cytometry. 
The flow cytometry samples were washed in flow buffer (60 mL 0.5% sodium 
azide solution, 87 mL PBS, and 3 mL FBS) and the cells were pelleted.  The cells from 
each sample were stained with 200 µL fluorescein isothiocyanate-labeled cat anti-FHV 
polyclonal antibody (Accurate Chemical and Scientific Corp., Westbury, NY) for one 
hour on ice.  The cells were washed in PBS and were resuspended in 1mL PBS per 
sample.  Cell surface fluorescence was assessed with an Epics XL flow cytometer 
(Beckman Coulter, Fullerton, CA).  
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 Western blot analysis:  Cells were combined with SDS sample buffer and boiled 
for five minutes.  Samples were stored at -20ºC until later assayed.  Proteins were 
electrophoresed on 10% polyacrylamide gels and transferred to nitrocellulose membranes 
(Bio- Rad, Hercules, CA).  The membranes were probed with CRFK adsorbed cat anti-
FHV-1 polyclonal antibody (Accurate Chemical and Scientific Corp.) or an anti-GAPDH 
monoclonal antibody (Chemicon International- Millipore, Billerica, MA), and an anti-β 
actin monoclonal antibody (Ambion) was used as a loading control.  Samples were 
incubated for 1 hour on a shaker at room temperature.  The membranes were washed five 
times and probed with peroxidase labeled goat anti-mouse IgG (GAPDH and beta actin 
monoclonals) or peroxidase labeled goat anti-feline IgG (FHV polyclonal) secondary 
antibodies (KPL, Gaithersburg, Maryland) for one hour on a shaker at room temperature.  
Five additional washes were performed, and proteins were detected by enhanced 
chemiluminescnece (Amersham Biosciences, Piscataway, NJ).  The density of the protein 
bands was determined with a visible scanning densitometer (Quick Scan 2000, Helena 
Laboratories, Beaumont, TX). 
RNA extraction and real-time RT-PCR:  Total RNA was extracted from 100 µL 
aliquots of each test and control sample with the RNeasy Mini Kit (Qiagen, Valencia, 
CA) according to manufacturer’s protocol.  Two on-column DNase digestions (Qiagen) 
were performed for each RNA sample, and the samples were diluted 1:1000 to reduce 
DNA contamination.  Purified RNA samples were stored at -80˚C until tested by real-
time RT-PCR.  Primers and probes for real-time RT-PCR were designed with Primer3 
(32) to detect FHV-1 DNA polymerase and interferon β mRNA (Table 2.2).  28S rRNA 
was used as a control to standardize RNA concentration (Table 2.2).  Primers, probe, and  
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TABLE 2.2  Primers and probes used to detect mRNA. 
 



































































RT-PCR cycling parameters for feline GAPDH were previously published (28) (Table 
2.2).  RT-PCR was performed for each transcript using the SuperScript III Platinum One-
Step qRT-PCR kit (Invitrogen).  5 µL of diluted RNA was used in 25 µL total volume 
reactions, which contained 200nM of each probe and 300nM of each primer, and 40U of 
RNaseOut recombinant ribonuclease inhibitor (Invitrogen).  Amplification of FHV-1 
DNA polymerase was carried out in a SmartCycler® II (Cepheid, Sunnyvale, CA) with 
the following parameters: cDNA production at 45ºC for 30 min, hot start Taq polymerase 
activation at 95ºC for 2 minutes, followed by 45 cycles of denaturation at 95ºC for 15 
seconds, annealing at 55ºC for 60 seconds, and extension at 72ºC for 30 seconds.  The 
parameters for interferon β and 28S rRNA were as follows: cDNA production at 42ºC 
(interferon) or 50ºC (28S) for 30 minutes, 95ºC for two minutes, followed by 45 cycles of  
95ºC for 15 seconds, 60ºC (interferon) or 62ºC (28S) for sixty seconds, and 72ºC for 30  
 
seconds.  Extensive DNA contamination was ruled out by RTase negative controls, which  
 
were run with Platinum taq (Invitrogen) instead of SuperScript III.  Each set of samples  
 
was run with three mRNA standard dilutions, generating curves for mRNA quantitation. 
 
mRNA standards and standard curve production:  mRNA standards were 
produced for FHV-1 DNA polymerase and feline GAPDH by ligating each PCR product 
into a pCR2.1 plasmid vector, and the recombinants were transduced into Escherichia 
coli (TA Cloning Kit, Invitrogen).  The plasmids were isolated (SNAP MiniPrep Kit, 
Invitrogen), and the identity and orientation of the cloned products were determined by 
sequencing (Molecular Biology Resources Service, University of Tennessee, Knoxville, 
TN).  The plasmids were linearized (Hind III, Fisher Scientific), and used for in vitro 
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transcription (AmpliCap T7 High Yield Message Maker Kit-Epicentre Biotechnologies, 
Madison, WI).  Following treatment with DNase (Qiagen), the mRNA transcripts were 
purified (RNeasy Mini Kit, Qiagen).  These standards were used to produce standard 
curves for absolute quantitation of FHV-1 DNA polymerase and feline GAPDH mRNA 
transcripts isolated from the samples.  The RNA concentration and purity of the standards 
were determined by spectrophotometrical analysis at OD 260/280 (BioPhotometer 6131 
spectrophotometer, Eppendorf, Westbury, NY).  The number of RNA copies in the 
sample was estimated based on the molecular weight of the RNA standards and the RNA 
concentration.  Ten fold serial dilutions of the RNA stock were prepared, and aliquots 
were made and frozen immediately at −80°C.  Each aliquot was used only once for real-
time RT-PCR.  
A standard curve was generated by testing 10-fold serial dilutions of the standard 
RNA by real-time RT-PCR and the standard curve was generated by the SmartCycler® II 
software (Cepheid).  The intra-assay and inter-assay coefficients of variation of the 
reactions were determined using dilutions of the standard RNA as previously described 
(33).  To ensure the standard RNA and the target RNA were amplified with similar 
efficiencies according to the calculation: Efficiency = [10(-1/slope)] -1 (40), four 10-fold 
serial dilutions of RNA extracted from a CRFK control well and an FHV infected control 
well were also prepared and tested in quadruplicate by real-time RT-PCR. 
Statistical analysis:  The results for the DNA polymerase specific siRNA test and 
control groups were compared by using univariate ANOVA (SPSS software) because all 
assumptions were met, based on the Levene’s test for equality of variances and the 
Shapiro-Wilk test for normality.  The real-time RT-PCR results for GAPDH specific 
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siRNA control groups were compared using the Mann-Whitney Test because the results 
lacked a normal distribution.  Univariate ANOVA and a Post Hoc Dunnett T3 test were 
used to compare controls with GAPDH specific siRNA treatment groups because there 
were unequal variances between treatment groups. 
Results 
RNAi of feline GAPDH:  In order to determine if RNAi could be performed in 
CRFK cells with siRNAs transfected with Lipofectamine 2000, an endogenous gene, 
feline GAPDH, was chosen as a target.  CRFK cells were transfected with each GAPDH 
specific siRNA separately and compared to negative control siRNA transfected cells and 
mock-transfected cells.  Forty-eight hours following transfection, knockdown of GAPDH 
mRNA was assessed by quantitative real-time RT-PCR.  RNA was standardized by 28S 
rRNA, which had a reaction efficiency of 102% (data not shown).  GAPDH mRNA copy 
numbers were calculated from the standard curve, which was linear over five orders of 
magnitude (slope = -3.299) and resulted in a theoretical limit of detection of 24 copies 
(Figure 2.1).  The intra-assay variation within the portion of the curve used for mRNA 
copy calculations was 10-35% based on copy numbers (0.58-1.95% based on Ct values), 
and the inter-assay variation was 18-43% based on copy numbers (1.15-2.26% based on 
Ct values).  The GAPDH specific siRNA, GAP1, GAP2, and GAP3, resulted in 
decreased GAPDH mRNA by 86%, 83%, and 93%, respectively, compared to the 
control, which consisted of an average of the results from the negative control siRNA 
transfected and mock-transfected CRFK cells (Figure 2.2).  The knockdown of GAPDH  
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FIGURE 2.1  GAPDH standard curve.  The GAPDH standard curve was generated by 
testing five 10-fold serial dilutions of GAPDH standard RNA, and the theoretical limit of 
detection was 24 copies.  The efficiency of the reaction was 101%, compared to the 

































FIGURE 2.2  Knockdown of feline GAPDH mRNA by siRNAs.  CRFK cells were 
transfected with feline GAPDH specific siRNAs (GAP1, GAP2, GAP3) or negative 
control siRNA.  Following 48 hours incubation, total RNA was extracted from cells and 
tested by real-time RT-PCR with primers specific for GAPDH mRNA or 28S rRNA.  
The samples were normalized with 28S rRNA and copies of GAPDH mRNA were 
estimated from a standard curve generated by 10-fold serial dilutions of a GAPDH RNA 
standard.   Three independent experiments were performed and the results show the 
means of the experiments; error bars represent 1 standard deviation from the means.  
GAP1 is statistically different than the control (P= 0.026), GAP2 is statistically different 
than the control (P= 0.029), and GAP3 is statistically different than the control (P= 0.019) 
based on statistical analysis.  Control = average of results from mock-transfected and 
negative control siRNA transfected CRFK cells (not statistically different, P= 1).  
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mRNA was independent of type 1 interferon production, determined by insignificant 
interferon β mRNA production in siRNA treated cells (similar to the amount detected in 
mock-transfected cells) compared to the control, CRFK cells infected with feline 
calicivirus, an interferon β activator (data not shown).   
GAPDH mRNA knockdown also resulted in reduced GAPDH protein expression.  
GAPDH protein was reduced by 43%, 24%, and 64%, by GAP1, GAP2, and GAP3, 
respectively, compared to non-treated and negative siRNA treated controls (Figure 2.3).   
Knockdown of DNA polymerase mRNA by RNAi:  Following the successful 
knockdown of GAPDH in CRFK cells by RNAi, we next evaluated RNAi directed 
against the DNA polymerase gene of FHV-1 in CRFK cells.  CRFK cells were 
transfected separately with each of the five siRNAs designed to target the FHV-1 DNA 
polymerase mRNA or with negative control siRNA in six well plates 24 hours prior to 
infection with FHV-1, and these samples were compared to a non-transfected, FHV-1 
infected control.  Forty-eight hours following infection, total RNA was extracted and 
tested for FHV-1 DNA polymerase mRNA by quantitative real-time RT-PCR.  The RNA 
in each sample was normalized with 28S rRNA.  Copies of mRNA were calculated from 
the standard curve, which was linear (slope = -3.406), spanning six orders of magnitude, 
and resulted in a theoretical detection limit of 15 copies (Figure 2.4).  The results were 
reproducible, with intra-assays of variation of 6-15% based on copy numbers (0.33-
0.91% based on Ct values) and inter-assays of variation of 14-21% based on copy 
numbers (0.73-1.44% based on Ct values) within the portion of the curve used to 
calculate DNA polymerase mRNA copies.  Two of the five siRNAs tested produced 
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FIGURE 2.3  Reduction of GAPDH protein expression by siRNAs.  CRFK cells were 
transfected with 100 nM each of feline GAPDH specific siRNAs (GAP1-3) and total 
cellular material was harvested after 48 hours incubation.  Western blot analysis was 
performed with anti-GAPDH and anti-beta actin monoclonal antibodies.  Each siRNA 
was run in duplicate (a,b) with a CRFK control transfected with negative control siRNA 
(N) and a CRFK mock-transfected control (C).  Beta-actin was used as a loading control 
to normalize protein concentrations, and the density of the protein bands was determined 





FIGURE 2.4 DNA polymerase standard curve.  The FHV-1 DNA polymerase standard 
curve was generated by testing six 10-fold serial dilutions of DNA polymerase standard 
RNA, and the theoretical limit of detection is 15 copies.  The efficiency of the reaction 
was 97-100%, compared to the efficiency of 10-fold serial dilutions of DNA polymerase 
mRNA of 105% (not shown).  Therefore, this standard curve was suitable for estimation 
of copy numbers of DNA polymerase mRNA. 
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significant reduction in DNA polymerase mRNA compared to the control, resulting in 
83% reduction by DNA1 and 69% reduction by DNA3 (Figure 2.5).  RNAi knockdown 
of the DNA polymerase mRNA was independent of type 1 interferon production (Figure 
2.6). 
Reduction in FHV-1 protein expression by RNAi:  Knockdown of FHV-1 DNA 
polymerase by DNA1 and DNA3 also resulted in decreased expression of FHV-1 
proteins in treated cells compared to negative siRNA control treated cells and untreated, 
FHV-1 infected cells.  Total protein was isolated from the infected cells and tested by 
Western blot (Figure 2.7); cells were also tested by flow cytometry to determine the                                  
amount of FHV-1 proteins on the surface of FHV-1 infected, DNA polymerase specific 
siRNA treated cells versus FHV-1 infected, negative siRNA control treated cells (Figure 
2.8).  DNA1 reduced cell surface FHV-1 glycoproteins on infected cells by 71% and 
DNA3 reduced cells surface FHV-1 glycoproteins by 29%, compared to the negative 
control siRNA treated cells. 
FHV-1 DNA polymerase specific siRNAs inhibit FHV-1 replication in vitro:  As 
expected and suggested by the decreased viral protein expression in DNA1 and DNA3 
treated cells, RNAi directed against FHV-1 DNA polymerase mRNA inhibited 
replication of the virus in CRFKs.  Infectious FHV-1 was detected in the cell culture 
supernatants of siRNA treated cells and controls by plaque assay.  DNA1 siRNA 
inhibited FHV-1 replication by 96%, and DNA3 by 83%, compared to the control (Figure 
2.9).  Inhibition of replication was also evident by the indirect knockdown of the 




































FIGURE 2.5  Knockdown of FHV-1 DNA polymerase mRNA by siRNAs.  CRFK 
cells were transfected with FHV-1 DNA polymerase specific siRNAs (DNA1 and 
DNA3) or negative control siRNA 24 hours prior to infection with FHV-1 (MOI= 0.1).  
Following 48 hours incubation, total RNA was extracted from cells and tested by real-
time RT-PCR with primers specific for DNA polymerase or 28S rRNA.  The samples 
were normalized with 28S rRNA and copies of DNA polymerase mRNA were estimated 
from a DNA polymerase standard curve generated by 10-fold serial dilutions of a DNA 
polymerase RNA standard.   Three independent experiments were performed and the 
results show the means of the experiments; error bars represent 1 standard deviation from 
the means.  DNA1 is statistically different than the control (P= 0.006) and DNA3 is 
statistically different than the control (P= 0.015) based on univariate ANOVA analysis.  
Control =  average of the results from non-treated and negative control siRNA treated 







FIGURE  2.6  Interferon β real-time RT-PCR.  Knockdown of FHV-1 DNA 
polymerase mRNA is siRNA specific and not the result of type 1 interferon induction.  
Interferon β mRNA copy numbers in samples treated with DNA1/DNA3 (b) are similar 
to the copy numbers detected in the untreated samples (b) and are much lower than the 
copy numbers detected in cells infected with calicivirus (a), an interferon β inducer. 
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FIGURE 2.7  FHV-1 DNA polymerase specific siRNAs knockdown FHV-1 protein 
expression.  Negative control siRNA (C) or FHV-1 DNA polymerase specific siRNAs 
(DNA1/DNA3) were transfected into CRFK cells 24 hours prior to infection with FHV-1 
(MOI = 0.1).  48 hours following FHV-1 infection, total cellular material was 
electrophoresed on 10% SDS polyacrylamide gels.  Proteins were transferred to 
nitrocellulose membranes, and membranes were probed with anti-FHV-1 polyclonal 
antibodies or an anti-GAPDH monoclonal antibody, as indicated. 
1- Negative control siRNA treated, FHV-1 infected cells (N); 2-non-treated, non-infected 
cells (C); 3 & 4- duplicates of DNA1 treated, FHV-1 infected cells; 5 & 6- duplicates of 
DNA3 treated, FHV-1 infected cells 
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FIGURE 2.8  FHV-1 DNA polymerase specific siRNAs decrease expression of FHV-
1 proteins on the surface of infected CRFK cells.  Cells were transfected with negative 
control siRNA, or FHV-1 DNA polymerase specific siRNA, DNA1 (a) or DNA3 (b), 24 
hours prior to FHV-1 infection (MOI = 0.1).   48 hours following infection, cells were 
incubated with anti-FHV-1 polyclonal antibodies.  Fluorescence intensity increases from 
left to right, and 104 cells/sample were analyzed.  The data are representative of three 
independent experiments.  Color key:  black- uninfected CRFKs, gray- FHV-1 infected, 
DNA polymerase specific siRNA treated CRFKs, white- FHV-1 infected, negative 























FIGURE 2.9  FHV-1 DNA polymerase specific siRNAs inhibit FHV-1 replication in 
CRFK cells.   Cells were transfected with negative control siRNA, or DNA polymerase 
specific siRNA (DNA1/DNA3), 24 hours prior to FHV-1 infection (MOI= 0.1).  48 hours 
following infection, cell culture supernatant was collected and tested in duplicate by 
plaque assay.  The experiment was repeated three times, and the results are shown as 
averages from the three experiments, with error bars representing 1 standard deviation 
from the means.  The titers from the DNA1 and DNA3 treated samples are statistically 
different from the titers for the untreated and negative siRNA treated control samples 





























FIGURE 2.10  Decreased FHV-1 glycoprotein D mRNA by DNA polymerase 
specific siRNA treatment.  CRFK cells were transfected with FHV-1 DNA polymerase 
specific siRNAs (DNA1 or DNA3) or negative control siRNA (C) 24 hours prior to 
infection with FHV-1 (MOI= 0.1).  Following 48 hours incubation, total RNA was 
extracted from cells and tested by real-time RT-PCR with primers specific for FHV-1 




We used RNAi to target the DNA polymerase gene of feline herpesvirus 1 and 
demonstrated significant suppression of viral replication by knockdown of the DNA 
polymerase mRNA.  Based on the results of this study, the FHV-1 DNA polymerase gene 
is an excellent target for RNAi anti-viral treatment. 
FHV-1 is a suitable virus for targeting by RNAi.  The virus, in the vast majority 
of cases, produces a localized respiratory infection (9).  Therefore, no systemic 
administration of siRNAs is necessary, eliminating the challenge of targeted delivery.  In 
vivo studies have already demonstrated the effective uptake of siRNAs from mucosal 
surfaces (29), including effective intranasal delivery of siRNAs for treatment of 
respiratory viruses (5, 21).  RNAi has also been shown to be effective in treatment of 
ocular disease (18). 
A potential benefit of using RNAi therapy for treatment of chronic FHV-1 ocular 
infections is the relatively long-term silencing obtained with RNAi.  In this study, we 
showed knockdown that lasted at least 72 hours after a single transfection.  Therefore, 
unlike the current herpesvirus antiviral treatments which must be applied 4-6 times per 
day to be effective (35), siRNAs could be used much less frequently.   
Silencing can be enhanced by consecutive applications of siRNAs into virus 
infected cells; however, this can lead to selection of mutants that have changes in the 
target region (39), especially in chronic infections with RNA viruses that produce 
quasispecies populations (19).  FHV-1 is a DNA virus and due to lower mutation 
frequencies of DNA viruses, escape mutation is not expected to be a significant problem 
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(12).  Targeting conserved regions in essential genes is also less likely to lead to 
mutational escape, and in targeting these genes, replication of the virus can be inhibited 
(29). 
Targeting conserved regions also mitigates the problem of sequence diversity 
between viral isolates (29).  Fortunately, FHV-1 has an apparently low rate of genetic 
variability between isolates (13).  The region of the DNA polymerase gene targeted in 
this study codes for highly conserved amino acid motifs of herpesvirus DNA polymerase 
genes, is unique to each viral species, and lacks DNA sequence drift for 
alphaherpesviruses, including herpes simplex virus type 2 (36) and feline herpesvirus, as 
determined in this study.   
Development of escape mutants has been shown to be prevented or decreased by 
using a combination siRNAs targeting different parts of the viral genome (39).  Also, 
targeting multiple genes has been shown to be more effective than targeting a single gene 
(29).  Therefore, a better method of FHV-1 RNAi would also incorporate siRNAs that 
target another essential gene.  One candidate is FHV-1 glycoprotein D (see Part 3).  
This study lays the groundwork for potential in vivo investigations in cats, the 
natural host of this virus, and a model that more closely resembles the HSV-1 infection in 
humans, compared to rabbit or mouse HSV-1 models (27).  Such studies may provide 
unique insights into the prevention/treatment of herpesvirus infections by RNAi. 
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Part 3  Feline herpesvirus 1 glycoprotein D is essential for in 
vitro replication and is a potential target for antiviral therapy 
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Abstract 
 RNA interference (RNAi), a gene regulatory mechanism conserved in eukaryotes, 
has been successfully reprogrammed in mammalian cells to inhibit expression of viral 
genes, functioning in anti-viral defense, similar to its natural biological role in plants.  
Inhibiting viral genes in infected cells has allowed determination of the role of those 
genes in infection.  In this study, we used RNAi to examine the function of feline 
herpesvirus 1 (FHV-1) glycoprotein D in the infection of feline cells.  We determined 
that glycoprotein D is necessary for production of infective virions, suggesting FHV-1 
glycoprotein D is necessary for viral attachment and/or penetration of host cells, similar 
to its counterpart in the related virus, herpes simplex type 1.  Two chemically produced 
siRNAs targeting the glycoprotein D gene significantly reduced virus titers in treated 
cells; therefore, this gene is a potential target for RNAi anti-viral therapy. 
Introduction 
RNA interference (RNAi) is a RNA-guided gene regulatory mechanism that is 
found in a variety of eukaryotic organisms, including yeast, plants, and mammals.  This 
cellular machinery is known to be activated by double-stranded RNA (9), which is 
chopped into duplexes of approximately 21 nucleotides called small interfering RNAs 
(siRNAs) (8) by a member of the RNase III family of ATP-dependent ribonucleases 
called Dicer (3).  The siRNA duplexes are incorporated into the RNA induced silencing 
complex (RISC).  RISC then targets homologous transcripts by base pairing and cleaves 
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the mRNA (11).  The mRNA is further degraded by exonucleases (for a review, see 
reference 10).     
siRNAs can be produced and delivered to cells to silence specific genes of 
interest, and chemically produced siRNAs of 21 nucleotides have been used routinely for 
RNAi experiments since the time they were discovered to initiate RNAi in mammalian 
cells (7).  RNAi can also be activated in mammalian cells by longer siRNAs, 27-mers, 
which were shown to be more potent inducers of RNAi than 21-mers.  These longer 
siRNAs are processed by Dicer and therefore, the resultant siRNAs are more efficiently 
incorporated into RISC (17). 
RNA interference, initiated by exogenous siRNAs, has been used successfully in 
previous experiments to determine the function of viral genes (26, 27), and also used 
therapeutically for mammalian viral infections (reviewed in (16).  One method of 
suppressing viral replication in cells is by silencing viral attachment proteins (1) (30).   
Feline herpesvirus 1 (FHV-1) glycoprotein D, an envelope protein, is the viral 
hemagglutinin and an inducer of virus-neutralizing antibodies (22, 23).   This gene also 
appears to be highly conserved (36).  FHV-1 glycoprotein D may play an important role 
in the restriction of the host range of the virus to feline cells (24).  It is unknown if FHV-
1 glycoprotein D is a viral attachment protein, but in the related virus, herpes simplex 
virus type 1, glycoprotein D is an attachment protein and is essential for entry of the virus 
into cells (20, 21, 29). 
We hypothesized that FHV-1 glycoprotein D, like its homolog in herpes simplex 
virus type 1, is necessary for viral infection.  We used both 21-mer and 27-mer siRNAs to 
knockdown the expression of this gene and have shown that it is likely involved with 
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viral attachment and/or penetration and is an appropriate target for RNAi anti-viral 
treatment. 
Materials and Methods 
Cells and viruses:  Crandell-Reese feline kidney (CRFK) cells (ATCC, Manassas, 
VA) were propagated and maintained in Dulbecco’s minimal essential medium (DMEM) 
(Cambrex, Charles City, IA) supplemented with 5% heat-inactivated fetal bovine serum 
(Atlanta Biologicals, Lawrenceville, GA) and standard concentrations of penicillin, 
streptomycin and Fungizone (Cambrex) at 37˚C in a 5% CO2 incubator.  The FHV-1 
strain used was the prototype strain C-27 (ATCC).  A calicivirus wild-type strain used in 
the study was a generous gift from the Clinical Virology Laboratory, University of 
Tennessee College of Veterinary Medicine. 
 siRNAs and transfection:  Both 21-mer (Ambion- Applied Biosystems, Austin, 
TX) and 27-mer (IDT, Coralville, IA) siRNAs were used to target the glycoprotein D 
gene of FHV-1 (Table 3.1).  The 21-mers were designed by Ambion, and the 27-mers 
were designed with the IDT siRNA design tool.  These sequences were compared with 
known sequences in the GenBank database to decrease off-target effects by avoiding 
similar sequences in the feline genome.  The portion of the FHV-1 glycoprotein D coding 
sequence targeted by the siRNAs is identical in each of the isolates in the GenBank 
database, in the prototype strain used in the study, and in an additional 10 isolates (2003-
2006) obtained from the Clinical Virology Laboratory, University of Tennessee College 
of Veterinary Medicine.  Negative control 21-mer and 27-mer siRNAs were purchased 
from Ambion and IDT, respectively.  A Cy-5 labeled control siRNA (IDT) was used as a  
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TABLE 3.1  siRNA designed to target FHV-1 glycoprotein D mRNA. 
 
siRNA Antisense sequence (5’→3’) Location 
targeted 



























a.  Bold letters represent guide sequence subsequent to processing by Dicer, lower 
case letters represent 3’ overhangs 
b. Upper case letters represent guide sequence, lower case letters represent 3’ 
overhangs 
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transfection control.  Transfections were performed with Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) in Opti-MEM (Gibco-Invitrogen), according to manufacturer’s protocol.  
Five µL of Lipofectamine 2000 was used to transfect 100 nM 21-mer siRNAs per well  
and 50 nM 27-mer siRNAs per well in six well plates.  Approximately 5 x 104 CRFK 
cells diluted in DMEM, supplemented with 10% FBS, were added to each well 
containing the transfection mixtures.  Plates were incubated for 24 hours prior to 
infection with FHV-1.  Each siRNA was tested in duplicate, and functional siRNAs were 
retested for a total of three experiments per siRNA.  Additional controls used for each 
experiment included uninfected/non-transfected CRFK cells, infected/non-transfected 
cells, and an interferon β control, which consisted of non-transfected CRFK cells infected 
with feline calicivirus, an RNA virus that activates interferon β in CRFK cells.  
Plaque assays:  FHV-1 strain C-27 was grown in CRFK cells until 50% 
cytopathic effect was produced.  The titer of the virus was determined by plaque assay as 
previously described (5), with the exception of using an agarose overlay.  Instead, serum 
from a cat with an IFA titer of >1:2560 (a gift from the University of Tennessee Clinical 
Virology Lab) was used at a dilution of 1:50. 
Transfected CRFK cells were infected with FHV-1 at a MOI of 0.1.  One hour 
after incubation, the cells were washed with DMEM and fresh DMEM supplemented 
with 10% FBS was added to each well.  Infected cells were incubated for a total of 48 
hours.  500 µL of cell culture medium was removed from each well after 48 hours and 
stored at -80˚C for plaque assay.  Infective virus titers (PFU) were determined for each 
well by plaque assay.  
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Flow cytometry:  Prior to infection with FHV-1, (24 hours after transfection) the 
transfection control well was tested to determine transfection efficiency.  The cells were 
trypsinized and washed in phosphate buffered saline (PBS) (Gibco- Invitrogen) and flow 
buffer (60 mL 0.5% sodium azide solution, 87 mL PBS, and 3 mL FBS), and 
resuspended in 1 mL PBS.  Transfection efficiency was determined by analyzing 
intracellular Cy-5 fluorescence with a Beckman Coulter Epics XL flow cytometer 
(Fullerton, CA).  Following FHV-1 infection and 48 hours incubation, the cells in each 
test and control well were trypsinized, washed with PBS, and resuspended in 1 mL of 
PBS per sample.  100µL of each suspension was removed and placed on ice for RNA 
extraction, and the rest of each sample was processed for flow cytometry.  The flow 
cytometry samples were washed in flow buffer, divided in half, and the cells were 
pelleted.  Half of each sample was stained with 200 µL fluorescein isothiocyanate-labeled 
anti-FHV-1 polyclonal antibody (Accurate Chemical and Scientific Corp., Westbury, 
NY) and the remainder was stained with the primary monoclonal antibody FHV 7-5, a 
generous gift from Dr. Chris Grant (Custom Monoclonals International, Sacramento, CA) 
at a dilution of 1:50 in PBS for 1 hour on ice.  The cells were then washed and the cells 
previously treated with the primary antibody were treated with 2 µL of the secondary 
antibody, fluorescein isothiocyanate-labeled F(ab’)2  rabbit anti-mouse immunoglobulin 
G (Southern Biotech, Birmingham, AL) for one hour on ice.  The cells treated with the 
polyclonal antibody were resuspended in 1 mL PBS per sample and stored at 4˚C until 
analyzed.  After a final wash for the remaining cells, they were resuspended in 1mL PBS 
per sample, and all the samples were analyzed by flow cytometry.  
 100
 RNA extraction and real-time RT-PCR:  Total RNA was extracted from 100 µL 
aliquots of each test and control sample with the RNeasy Mini Kit (Qiagen, Valencia, 
CA) according to manufacturer’s protocol.  The RNA samples were treated with two on-
column DNase digestions (Qiagen) and diluted 1:1000 to reduce DNA contamination.  
Purified RNA samples were stored at -80˚C until tested by real-time RT-PCR.  Primers 
and probes for real-time RT-PCR were developed with Primer3 (32) to detect FHV-1 
glycoprotein D and interferon β mRNA (Table 3.2).  28S rRNA was used as a control to 
standardize RNA concentration (Table 3.2).  Real-time RT-PCR was performed for each 
transcript using the SuperScript III Platinum One-Step qRT-PCR kit (Invitrogen) in a 
SmartCycler® II (Cepheid, Sunnyvale, CA).  Five µL of diluted RNA was used in 25 µL 
total volume reactions, which contained 200 nM of each probe and 300 nM of each 
primer.  The reaction conditions for glycoprotein D and interferon β were  
reverse transcription at 42ºC for 30 minutes, an initial heat step of 95ºC for two minutes 
to activate the hot start Taq polymerase, followed by 45 cycles of 95ºC for 15 seconds, 
50ºC (glycoprotein D) or 60ºC (interferon β) for 60 seconds, and 72ºC for 30 seconds.  
The reaction conditions for 28S rRNA were reverse transcription at 50ºC for 30 minutes, 
95ºC for two minutes, and 45 cycles of  95ºC for 15 seconds,  62ºC for 60 seconds, and 
72ºC for 30 seconds.  RTase negative controls were run using Platinum Taq (Invitrogen), 
replacing SuperScript III, to rule out excessive DNA contamination.  Each set of samples 
was run with mRNA standard dilutions to validate mRNA quantitation. 
mRNA standards and standard curve production:  mRNA standards were 
produced for glycoprotein D and interferon β by cloning the PCR products into plasmid 
vectors and transducing Escherichia coli (TA Cloning Kit, Invitrogen).  Recombinant  
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TABLE 3.2  Primers and probes used to detect mRNA. 
 

















































plasmids were isolated (SNAP MiniPrep Kit, Invitrogen), sequenced (Molecular Biology 
Resources Service, University of Tennessee, Knoxville, TN), linearized (Hind III, Fisher 
Scientific), and used for in vitro transcription (AmpliCap T7 High Yield Message Maker 
Kit-Epicentre Biotechnologies, Madison, WI).  mRNA transcripts were treated with 
DNase (Qiagen) and purified (RNeasy Mini Kit, Qiagen).  These standards were used to 
produce standard curves for absolute quantitation of glycoprotein D and interferon β 
mRNA transcripts isolated from the samples.  The RNA concentration and purity of the 
mRNA standards was determined with a BioPhotometer 6131 spectrophotometer 
(Eppendorf, Westbury, NY).  The numbers of RNA copies were estimated based on the 
molecular weights of the RNA standards and the RNA concentrations.  Ten-fold serial 
dilutions were prepared, and aliquots of each dilution were stored at -80° C and used only 
once. 
Standard curves were generated by testing dilutions of the standard RNAs by real-
time RT-PCR and the standard curves were generated by the SmartCycler® II software 
(Cepheid).  The intra-assay and inter-assay coefficients of variation of the reactions were 
determined using dilutions of the standard RNAs as previously described (34).  To ensure 
the standard RNAs and the target RNAs were amplified with similar efficiencies (based 
on the calculation: Efficiency = [10-1/slope)] -1) (38), four 10-fold serial dilutions of RNA 
extracted from an FHV infected control well and RNA extracted from a Calici infected 
interferon β control well were also prepared and tested by real-time RT-PCR. 
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Results 
FHV-1 glycoprotein D specific siRNAs inhibit glycoprotein D mRNA and 
protein expression:  To examine if glycoprotein D expression could be knocked down by 
RNA interference, three 27-mer and three 21-mer siRNAs were designed to target five 
different areas of glycoprotein D mRNA.  The siRNAs were transfected into cells prior to 
infection with FHV-1.  CRFK cells were effectively transfected with Lipofectamie 2000, 
with efficiencies of 95% and greater, based on results from a transfection control siRNA 
(data not shown).   
Quantitative real time RT-PCR was used to determine glycoprotein D mRNA 
knockdown 48 hours after infection.  mRNA copy numbers for each sample were 
estimated from a standard curve generated by dilutions of standard glycoprotein D RNA.  
The standard curve spanned five orders of magnitude, and the curve showed linearity 
over the entire range used for quantitation of mRNA (Figure 3.1).  The results were 
reproducible, with an intra-assay coefficient of variation based on copy numbers of 10-  
21% (0.5-1.24% based on Ct values) and an inter-assay coefficient of variation of 34-
52% based on copy numbers (1.33-3.40% based on Ct values).  The theoretical limit of 
detection was 20 copies of glycoprotein D mRNA. 
Of the siRNAs tested, one of the 27-mers (gD1) and one of the 21-mers (G3) were 
shown to be highly effective, with knockdown of glycoprotein D mRNA by 77% by gD1 
and 87% by G3, whereas the rest of the siRNAs were shown to have minimal to moderate 
effects compared to control samples transfected with negative control siRNAs (Figure 3.2 
and data not shown).  The least functional siRNAs, producing approximately 30%  
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FIGURE 3.1  FHV-1 glycoprotein D standard curve.  The curve was generated by 
testing five 10-fold serial dilutions of glycoprotein D standard RNA.  The efficiency of 
the reaction was 100%, compared to the efficiency of 10-fold serial dilutions of 
glycoprotein D mRNA of 101% (not shown).  Therefore, this standard curve is suitable 




























FIGURE 3.2  Knockdown of FHV-1 glycoprotein D mRNA by siRNAs.   CRFK cells 
were transfected with gD1 siRNA, G3 siRNA, or negative control siRNA 24 hours prior 
to infection with FHV-1 (MOI= 0.1).  Following 48 hours incubation, total RNA was 
extracted from cells and tested by real-time RT-PCR with primers specific for 
glycoprotein D or 28S rRNA.  The samples were normalized with 28S rRNA and copies 
of glycoprotein D were estimated from the glycoprotein D standard curve.   The figure 
shows the results from a single representative experiment.  Three independent 
experiments were performed with similar results.  Control = averaged results from 21-
mer and 27-mer negative control siRNA treated FHV-1 infected cells (not statistically 




knockdown each, were the 27-mer gD2 and the 21-mer G1, which both targeted the same 
region of the coding sequence (data not shown).  Therefore, gD1 and G3 were chosen for 
additional experiments.   
gD1 and G3 siRNAs were also tested in cells infected with FHV-1 (MOI=1) 24 
hours following transfection and tested for mRNA knockdown 24 hours following 
infection.  G3 was effective under these reaction conditions, however; the 27mer gD1 
was not effective (data not shown).   
 Glycoprotein D protein synthesis was assessed in glycoprotein D specific siRNA 
treated versus negative siRNA treated cells by flow cytometry.  For this test, FHV-1 
monoclonal antibodies, donated by Dr. Chris Grant (Custom Monoclonals International), 
were characterized by Western blot analysis, flow cytometry, virus neutralization, and 
hemagglutination inhibition assays.  One monoclonal antibody (FHV 7-5) was shown to 
react with an antigen that is approximately 50-60 kDa in size (Figure 3.3), found on the 
surface of infected cells by flow cytometry, and inhibited hemagglutination of feline cells 
(Figure 3.4).  These results suggested this monoclonal detects FHV-1 glycoprotein D (22, 
23).  However, this monoclonal did not neutralize virus infectivity in the absence of 
complement as expected, but this is a variable characteristic based on epitope (23).  
Therefore, this antibody was used to assess the amount of glycoprotein D present on the 
surface of FHV-1 infected cells transfected with negative control siRNA or with 
glycoprotein D specific siRNAs.  Knockdown of glycoprotein D by gD1 and G3 siRNAs 
decreased glycoprotein D protein expression by 27% and 43%, respectively, compared to 
the negative siRNA transfected control (Figure 3.5).  
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FIGURE 3.3  Detection of FHV-1 glycoprotein D with FHV 7-5 monoclonal 
antibody.  Proteins from FHV-1 infected cells were treated with SDS sample buffer, 
electrophoresed on a 10% polyacrylamide gel and transferred to a nitrocellulose 
membrane (Bio- Rad, Hercules, CA).  The membrane was blocked overnight in 5% milk 
at 4ºC.  The membrane was probed with FHV 7-5 monoclonal antibody for 1 hour at 
room temperature.  The membrane was washed five times with PBS containing 0.05% 
Tween 20 and probed with peroxidase labeled goat anti-mouse IgG (KPL, Gaithersburg, 
Maryland) for one hour at room temperature.  Five additional washes were performed, 
and the protein was detected by enhanced chemiluminescence (Amersham Biosciences, 
Piscataway, NJ).   
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FIGURE 3.4  Inhibition of FHV-1 hemagglutination by FHV 7-5.  A 
hemagglutination inhibition test was performed with monoclonal FHV 7-5 and treated 
FHV-1 infected CRFK cells by using 0.5% (v/v) feline red blood cells as previously 
described (23).  C represents the control well, which lacked FHV-1, and the numbers 
represent the inverse of two-fold serial dilutions of antibody.     
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FIGURE 3.5  FHV-1 glycoprotein D specific siRNAs decrease expression of gD 
protein on the surface of infected CRFK cells.  Cells were transfected with negative 
control siRNA, gD1 (a) or G3 (b) 24 hours prior to FHV-1 infection (MOI = 0.1).   48 
hours following infection, cells were incubated with FHV 7-5 monoclonal antibody (gD 
specific monoclonal) and FITC labeled (ab’)2  rabbit anti-mouse immunoglobulin G.  
Color key:  white- uninfected CRFK cells, black- gD1/G3 treated FHV-1 infected cells, 
gray- negative control siRNA treated FHV-1 infected cells.  Fluorescence intensity 
increases from left to right, and 104 cells were analyzed/sample.  This experiment was 
repeated three times with similar results. 
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          FHV-1 glycoprotein D specific siRNAs inhibit virus replication:  To determine if 
knockdown of glycoprotein D mRNA affects virus replication, plaque assays were 
performed to quantify the amount of infective virus released into cell culture 
supernatants.  gD1 was shown to inhibit viral replication by 84%, and G3 inhibited viral 
replication by 77%, compared to non-transfected and negative control siRNA transfected, 
FHV-1 infected cells (Figure 3.6)    
Glycoprotein D specific siRNAs inhibit FHV-1 DNA polymerase mRNA:  Based 
on the results from the replication study, we expected that interference of glycoprotein D 
mRNA should also result in an indirect decrease in all viral mRNAs due to replication 
inhibition.  So, the effect of gD1 and G3 treatment on FHV-1 DNA polymerase mRNA 
copy numbers was determined.  The RNA extracted from the cells was tested for FHV-1 
DNA polymerase mRNA by real-time RT-PCR with primers specific for FHV-1 DNA 
polymerase mRNA (see Part 2).  Though no significant decline in the DNA polymerase 
mRNA was detected from samples treated individually with gD1 or G3, when the 
siRNAs were used together (25 nM gD1, 75 nM G3) to transfect cells 24 hours prior to 
FHV-1 infection (MOI = 0.1), a decrease in the DNA polymerase mRNA was detected 
(Figure 3.7 and data not shown). 
Glycoprotein D specific siRNAs inhibit expression of additional cell surface 
proteins:  Knockdown of additional FHV-1 proteins by glycoprotein D specific siRNAs 
was also evaluated.  Known glycoproteins on the surface of FHV-1 infected cells in 
addition to glycoprotein D include glycoproteins B, C, and G, and the complex formed by 
glycoproteins E and I.  Polyclonal antibodies of feline origin were used to evaluate the 
























FIGURE 3.6  FHV-1 glycoprotein D specific siRNAs inhibit FHV-1 replication in 
CRFK cells.  Cells were transfected with negative control siRNA, gD1, or G3 24 hours 
prior to FHV-1 infection (MOI= 0.1).  48 hours following infection, cell culture 
supernatant was collected and tested in duplicate by plaque assay.  The experiment was 
repeated three times, and the results are shown as averages from the three experiments, 
with error bars representing 1 standard deviation from the means.  The titers from the 
gD1 and G3 treated samples are statistically different from the titers for the negative 
siRNA treated and untransfected control samples (Control), with P values of 0.005 and 




































FIGURE 3.7  Indirect decrease of FHV-1 DNA polymerase mRNA by glycoprotein 
D specific siRNAs.  CRFK cells were transfected with FHV-1 glycoprotein D specific 
siRNAs (25 nM gD1 siRNA and 75 nM G3 siRNA) or negative control siRNAs (25 nM 
27mer control, 75 nM 21mer control) 24 hours prior to infection with FHV-1 (MOI= 
0.1).  Following 48 hours incubation, total RNA was extracted from cells and tested by 
real-time RT-PCR with primers specific for DNA polymerase mRNA (see Part 2) or 28S 
rRNA.  The samples were normalized with 28S rRNA and copies of DNA polymerase 
mRNA were estimated from a DNA polymerase standard curve generated from ten-fold 
serial dilutions of DNA polymerase standard RNA (see Part 2). 
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and G3, when used independently, did not display much effect on the other 
glycoproteins; however, when used in combination (25 nM gD1, 75 nM G3), produced 
significant knockdown in surface FHV-1 glycoproteins on infected cells compared to 
negative control siRNA transfected, FHV-1 infected cells (Fig. 3.8 and data not shown). 
The siRNA effect produced by glycoprotein D specific siRNAs is specific:  The 
effect of virus replication suppression by knockdown of the glycoprotein D mRNA in this 
study had to be distinguished from non-sequence specific destruction of all viral mRNA 
transcripts as a result of induction of the type 1 interferon pathway (18).  Interferon 
induction has been ruled out in previous studies in epithelial cells by interferon β 
detection methods (4, 6).  A quantitative real-time RT-PCR assay for detection of 
interferon β mRNA in feline cells was designed and used to estimate copy numbers based 
on a standard curve produced from an RNA standard.  The standard curve generated by 
dilutions of the interferon β standard RNA spanned six orders of magnitude, and the 
curve showed linearity over the entire range used for quantitation of mRNA (Figure 3.9). 
The results were reproducible, with 7-43% intra-assay variation based on copy numbers 
(0.38-2.88%, based on Ct values) and 16-41% inter-assay variation based on copy 
numbers (0.67-2.87% based on Ct values).  The theoretical limit of detection was 25 
copies of interferon β mRNA.  Results from this study showed that the interferon β 
detected in siRNA treated cells was negligible compared to the control sample 
(calicivirus infected cells) and similar to the background level detected in infected cells, 
not transfected with siRNAs (data not shown).  Therefore, the suppression of viral 
replication was the result of the knockdown of glycoprotein D mRNA and not due to type 




FIGURE 3.8  FHV-1 glycoprotein D specific siRNAs decrease FHV-1 proteins on the 
surface of infected CRFK cells.  CRFK cells were transfected with FHV-1 glycoprotein 
D specific siRNAs (25 nM gD1 siRNA and 75 nM G3 siRNA) or negative control 
siRNAs (25 nM 27mer control, 75 nM 21mer control) 24 hours prior to infection with 
FHV-1 (MOI= 0.1).  Following 48 hours incubation, cells were incubated with 
fluorescein isothiocyanate-labeled anti-FHV-1 polyclonal antibody (Accurate Chemical 
and Scientific Corp., Westbury, NY).  Color key:  white- uninfected CRFK cells, black- 
gD1/G3 siRNA treated FHV-1 infected cells, gray- negative control siRNA treated FHV-
1 infected cells.  Fluorescence intensity increases from left to right, and 104 cells were 




FIGURE 3.9  Interferon β standard curve.  The curve was generated by testing six 10-
fold serial dilutions of interferon β standard RNA.  The efficiency of the reaction was 
100%, compared to the efficiency of 10-fold serial dilutions of interferon β mRNA of 
96% (not shown).  This standard curve was used for estimation of copy numbers of 




RNAi has been manipulated in previous experiments for the determination of 
viral gene function (19, 26, 27), and we have shown that RNAi can be effectively used in 
CRFK cells to knockdown FHV-1 glycoprotein D mRNA when transfected prior to 
infection, thereby allowing determination of the function of this gene.  Knockdown of 
FHV-1 glycoprotein D mRNA resulted in a decrease in the amount of glycoprotein D and 
other FHV-1 glycoproteins detected on the surface of infected cells, as well as indirect 
decrease of FHV-1 DNA polymerase mRNA, independent of the production of type 1  
interferon.  FHV-1 glycoprotein D, like its counterpart in herpes simplex virus type 1, is 
essential for producing infectious virions in vitro.   
Based on these results, we speculate that FHV-1 glycoprotein D is involved with 
viral attachment and/or penetration.  Knockdown of this protein on the viral envelope 
appears to impair entry of the virus into cells, resulting in a reduction in the amount of 
infectious virus compared to control samples, but not necessarily the amount of other 
viral mRNAs and proteins, except when knockdown is enhanced by using a combination 
of two highly functional siRNAs.   
Both 21-mer and 27-mer synthetic siRNAs were used in this study.  The 27-mers 
have been shown to be more potent inducers of RNAi compared to 21-mers and 
potentially functional at sites refractive to RNAi by 21-mer siRNAs (17).  Interestingly, 
Ambion designed a siRNA that targeted a site also determined suitable by the IDT design 
tool.  However, this particular site was refractory to RNAi by both types of siRNAs.  The 
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Mfold program (25, 39) was used to predict the glycoprotein D mRNA structure, and we 
discovered that despite the amenable sequence, the target site is likely self-annealed in a 
helix in its energetically most favorable structure (data not shown), which has been 
previously shown to inhibit RNAi (35). 
Also of interest, the 27-mer siRNA (gD1) was not functional in knockdown of 
glycoprotein D mRNA 24 hours after infection of cells with a multiplicity of infection of 
1, but the 21-mer (G3) was functional.  We attribute this to the fact that unlike the 21-
mer, the 27-mer has to be processed by Dicer.  RNA silencing is generally maximal at 
approximately 24 hours post-transfection (14).  However, in an RNAi study in rotavirus, 
the highest suppression was found to occur with infection of cells with rotavirus 72 hours 
after transfection with siRNAs, suggesting some of the elements of RNAi could be 
induced or activated by the presence of siRNAs, increasing their effective concentration 
inside the cell (2).   
We also discovered the 27-mer siRNAs were toxic to cells in a concentration 
dependent manner, likely resulting from off-target effects with increased concentrations 
of siRNA leading to a stress response within the cell (31).  Therefore, the 27-mer siRNA 
(gD1) was determined to be less toxic and functional at a concentration lower than what 
was used for the 21-mer siRNA (G3).  
Off-target effects may include stimulation and suppression of expression of genes 
unrelated to the intended target (31, 33). These effects appear to be sequence-related; 
siRNAs may cross-react with mRNAs of limited sequence homogeneity (13). Therefore, 
observing the same phenotype with multiple individual siRNAs targeting the same gene 
increases the confidence that the knockdown of the intended gene can be attributed to the 
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observed phenotype (14, 15).  We were able to show the same effects with two different 
siRNAs targeting two different areas of the glycoprotein D mRNA, strengthening our 
findings. 
FHV-1 glycoprotein D appears to function similarly to its counterpart in herpes 
simplex virus type 1 and is a suitable target for suppressing FHV-1 viral infection in 
cells.  It is therefore a potential target for anti-viral therapy; although, as a structural 
protein, it is not transcribed until “late” in infection, and may not be as good a target as a 
gene transcribed early in the infection process (16, 28), such as the FHV-1 DNA 
polymerase gene (see Part 2).  However, use of siRNAs targeting this gene could be 
successfully used in combination with siRNAs targeting the DNA polymerase gene, also 
reducing the potential for development of escape mutants (37), and likely will be more 
effective than targeting a single gene (30). 
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Part 4  General Summary 
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Feline herpesvirus 1 (FHV-1) glycoprotein D is an important contributor to the 
immune response to FHV-1 infection, and neutralizing antibodies against this protein are 
produced in cats during infection (9, 10).  The glycoprotein D homolog in the related 
alphaherpesvirus, herpes simplex virus type 1, contributes to host cell attachment and is 
necessary for entry of the virus into cells (7, 8, 11).  It was hypothesized that glycoprotein 
D has a similar role in FHV-1 infection and that this gene and the FHV-1 DNA 
polymerase gene would be appropriate targets to alter viral replication, by inhibiting 
entry of the virus into the cells (glycoprotein D) or by directly inhibiting replication of 
the viral genome (DNA polymerase).  RNA interference was used to knockdown the 
expression of FHV-1 glycoprotein D and DNA polymerase genes in CRFK cells.  In both 
experiments, knockdown of the intended target did result in suppression of virus 
replication in vitro. 
Knockdown of glycoprotein D mRNA in this study significantly decreased the 
amount of infectious virus released into the cell culture supernatant.  Knockdown of the 
mRNA with two highly functional siRNAs (70% knockdown or greater) transfected 
separately was not sufficient enough to knockdown other viral mRNAs, such as the DNA 
polymerase mRNA, or the expression of other viral glycoproteins.  This phenomenon was 
also seen in a previous study with RNAi of the rotavirus attachment protein, VP4 (3).  
However, when silencing of the glycoprotein D mRNA was enhanced by using the two 
siRNAs combined, significantly detectable knockdown of DNA polymerase mRNA and 
FHV-1 proteins on the surface of infected cells was achieved, with an obvious decrease 
in the amount of cytopathic effect (CPE) produced in cell culture. 
 124
RNAi does not prevent the initial entry of virions into the cells, and by targeting 
the glycoprotein D gene (a structural protein, transcribed late in infection), the first round 
of viral replication is unaffected.  Knockdown of glycoprotein D expression reduces the 
amount of the protein incorporated into the viral envelope, altering the infectivity of the 
virions and presumably inhibiting some but not all from infecting cells.  Therefore, when 
knockdown is enhanced, seemingly more virions are inhibited from infecting cells, 
resulting in a detectable decrease in the amount of viral mRNAs in addition to the 
glycoprotein D mRNA detected inside the cells and enough decrease in the number of 
replicating virions to have a significant suppressive effect on the expression of additional 
viral glycoproteins.  Unfortunately, the amount of viral DNA in the cell culture 
supernatants was not determined in this study, nor was the amount of infectious virus 
associated with the infected cells, to corroborate this idea.   Based on the findings in this 
study, though, glycoprotein D is a potential target for RNAi anti-viral therapy. 
However, targeting a gene transcribed earlier in viral infection likely will have a 
more significant affect on virus replication (4).  This was shown to be the case in this 
study.  Targeting the DNA polymerase gene of FHV-1, an early gene, resulted in 
significant reduction in cytopathic effect produced in cells treated individually with two 
different siRNAs (DNA1 and DNA3).  Compared to the controls (FHV infected/ non-
transfected and FHV infected/ negative control siRNA transfected cells), which contained 
3-4+ CPE, cells treated with DNA1 had 1-2+ CPE and cells treated with DNA3 had 2-3+ 
CPE.  By targeting the DNA polymerase gene, there is a direct reduction of viral 
replication, potentially starting with the first round of replication.  Therefore, though 
knockdown of the amount of DNA polymerase mRNA by DNA3 was significantly less 
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than what was achieved for glycoprotein D mRNA by the glycoprotein D specific 
siRNAs, there was better indirect knockdown of other viral mRNA (glycoprotein D) and 
viral proteins on the surface of infected cells with this individual DNA polymerase 
specific siRNA. 
For anti-viral therapy, targeting multiple viral genes is likely the best method to 
prevent production of escape mutants (17), and has been shown to be more effective in 
vivo in a herpesvirus study than targeting a single gene (12).  Thus, use of siRNAs 
targeting both the glycoprotein D and DNA polymerase genes is probably the best 
strategy for the most efficient suppression of FHV-1 replication, though this experiment 
was not performed in this study. 
In addition to choosing the best genes to target, efficient transfection of siRNAs 
into cells is important for successful RNAi experiments.  Efficient transfection was 
achieved in this study with Lipofectamine 2000; however, a suboptimal concentration of 
transfection reagent had to be used to reduce cellular toxicity.  The reagent was toxic to 
cells in a concentration dependent manner (data not shown).  Not all toxicity could be 
eliminated and cells showed mild granularity, with more dead cells in transfected samples 
compared to non-transfected controls. 
Also, transfection was unsuccessful in cells pre-plated in medium containing 
antibiotics 24 hours prior to transfection (data not shown); so, reverse transfections were 
used in this study, with cells added to transfection mixtures.  It was not determined if it 
was the antibiotics in the cell culture medium, or the plated cells, or a combination of 
both that prevented transfection of the plated cells.  The antibiotics in the medium during 
the transfection process did not kill the cells, and addition of antibiotics to the medium 
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four hours after transfection had no negative effects on the transfection efficiency.  
However, transfection was shown to be complete after four hours incubation, so 
antibiotics added at that point would not have affected transfection efficiency anyway.   
An additional observation concerning this transfection reagent was that 
concentrations of siRNA below 50 nM resulted in transfection efficiencies below 95% 
(data not shown).  So, determining the optimal concentration of siRNAs to obtain the 
highest knockdown with the least amount of cellular toxicity was not possible in the cell 
culture system used in this study with this transfection reagent.  Therefore, a different 
type of transfection reagent would likely be indicated for future studies. 
Design of siRNAs may be more important for effective targeting than the method 
of delivery of siRNAs into cells (5).  Chemically produced 21-mer and 27-mer siRNAs 
were used in this study.  27-mers were used because they had been shown to be more 
effective than 21-mers (6).  One of six 27-mers (3 glycoprotein D specific and 3 DNA 
polymerase specific) tested in this study was found to be highly functional (70% or 
greater knockdown of intended target).  Two of the 27-mers targeted the same regions as 
two of the 21-mers.  One of these 27-mers targeted the same sequence as one of the 
functional DNA polymerase specific 21-mer siRNAs, DNA3.  When initially tested, the 
27-mer designed to target this area produced 60% knockdown of DNA polymerase 
mRNA, less than the amount required to be considered highly functional, so it was not 
tested further (data not shown).  So, for this particular target area, the 21-mer seemed to 
function better, but optimal concentrations of the 27-mer were not determined and the 
increased potency of 27-mers is really only obvious at subnanomolar concentrations (6), 
which were not used in this study. 
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The sequence of each individual siRNA is obviously important to its function 
because it facilitates the association with RISC and subsequent degradation of target 
mRNA (5).  The most important criterion in siRNA design appears to be asymmetry in 
the stability of the duplex ends.  The 5’ end of the antisense strand should be less 
thermodynamically stable than the 3’ end (1, 13)  This facilitates the use of the antisense 
strand as the guide strand by RISC (5, 14).  Of the DNA polymerase specific siRNAs 
tested, the two most effective siRNAs contained 5’ ends that were less 
thermodynamically stable than the 3’ends, and the least functional siRNA (DNA2) had a 
more stable 5’ end. 
Also, in this study, as has been shown previously (16), the secondary structure of 
the target mRNA appeared to be an important determinant of whether some siRNAs 
would work well.  The other region targeted by both a 21-mer and 27-mer siRNA was 
within the glycoprotein D mRNA.  Neither siRNA was functional for this target region, 
which is predicted to be self-annealed in its energetically most favorable state and likely 
not accessible to the RNAi machinery.  The least functional DNA polymerase specific 
siRNA tested (DNA2) was also predicted to be completely self-annealed.  Whereas, the 
two most functional DNA polymerase specific siRNAs contained several bases that were 
in loop structures, including the 3’ end of the coding sequence targeted by DNA1, the 
most effective DNA polymerase specific siRNA in the study. 
Despite the complications in designing functional siRNAs, RNAi has been shown 
to be effective in the prevention/ treatment of infections by several different viruses (4).  
This study examined prevention of FHV-1 infection in vitro and because transfection of 
cells with siRNAs after infection was not performed, treatment of FHV-1 by RNAi was 
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not addressed.  FHV-1 replicates rapidly in cell culture.  Infectious intracellular virus can 
be detected six hours post infection, and cell-to-cell spread of virus can be detected six to 
seven hours post infection.  Extracellular spread of the virus occurs at nine to ten hours 
post infection, concurrent with detection of infectious extracellular virus (15).  Therefore, 
it is probable that RNAi, by itself, may not be very effective to treat an established 
infection, but a combination of RNAi and nucleoside analogs might encounter a 
synergistic effect (4) for treatment of chronic FHV-1 ocular infections in cats.  RNAi 
might be more useful for prevention of FHV-1 infections in situations associated with 
increased risk for respiratory disease, such as in breeding colonies and rescue catteries 
(2).  Or, RNAi could potentially be used to prevent the recrudescence of latent infections 
in chronically infected cats.  Regardless, with the current lack of effective treatments for 
this disease in chronically infected cats, RNAi has merit as a potential FHV-1 anti-viral 
therapy. 
This study lays the groundwork for potential in vivo investigations in cats.  Such 
studies may provide unique insights into the prevention/treatment of herpesvirus 
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